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Abstract 
 
SIGNS AND SYMPTOMS OF OPIOID WITHDRAWAL IN THE PEDIATRIC PATIENT 
DURING OPIOID TAPERING 
 
By Deborah Fisher, PhD, RN, CS, PNP-BC, CPON 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2012 
 
VCU Chair: Mary Jo Grap, PhD, RN, FAAN 
Professor, Adult Health and Nursing Systems 
School of Nursing 
 
Opioids are used routinely in the pediatric intensive care population for 
analgesia, sedation, blunting of physiologic responses to stress, and safety. In children, 
physical dependence may occur in as little as two to three days of continuous opioid 
therapy. Once the child no longer needs the opioid, the medications are reduced over 
time. A review of the literature revealed that the majority of the published studies used 
either a neonatal opioid assessment tool or no assessment tool. A subsequent 
international survey of pediatric providers found a wide range of opioid tapering 
practices and sporadic use of opioid withdrawal instruments to guide practice. Since 
tapering routines vary among practitioners, it is not uncommon to see signs and
  
 symptoms of opioid withdrawal. A prospective, descriptive study was conducted to 
describe the frequency of opioid withdrawal signs and symptoms and to identify factors 
associated with these opioid withdrawal signs and symptoms. The sample of 25 was 
drawn from all patients, ages 2 weeks to 21 years admitted to the Children’s Hospital of 
Richmond Pediatric Intensive Care Unit (PICU) and who have received continuous 
infusion or scheduled opioids for at least 5 days. Data collected included: opioid 
withdrawal score (WAT-1), opioid taper rate (total dose of opioid per day in morphine 
equivalents per kilogram [MEK]), pretaper peak MEK, pretaper cumulative MEK, 
number of days of opioid exposure prior to taper, and age. Out of 26 enrolled 
participants, only 9 (45%) had opioid withdrawal on any given day. In addition, there 
was limited variability in WAT-1 scores. The most common symptoms notes were 
diarrhea, vomit, sweat, and fever. For optimal opioid withdrawal assessments, clinicians 
should use a validated instrument such as the WAT-1 to measure for signs and 
symptoms of opioid withdrawal. Further research is indicated to examine risk factors for 
opioid withdrawal in children. 
 
Key Words: opioid withdrawal, opioid taper, opioid analgesia, critical care, child
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CHAPTER 1. INTRODUCTION 
 
Background and Significance 
Opioids are used routinely in the pediatric intensive care population for 
analgesia, sedation, blunting of physiologic responses to stress, and safety.1-3 The 
therapeutic goal of providing adequate analgesia and sedation often results in days to 
weeks of continuous exposure to opioids and sedative. Continued exposure may lead to 
iatrogenic opioid dependence. Opioid dependence is defined as a state of adaptation 
that is manifested by a drug class specific withdrawal syndrome that can be produced 
by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or 
administration of an antagonist. 4 Opioid withdrawal is a clinical response to the 
cessation of an opioid after continuous, prolonged exposure to that opioid.5 Therefore, it 
is clinically and ethically prudent to taper opioids in a safe manner with a goal of 
avoidance of opioid withdrawal.  
Presently, there is no gold standard for opioid tapering in children. A review of 
the literature of the empiric evidence to guide opioid tapering while avoiding opioid 
withdrawal in children is presented in Chapter 2.6  
The majority of published research has focused on the periodic incidence of 
withdrawal symptoms during opioid tapering. Only recently has a valid and reliable 
pediatric opioid withdrawal symptom assessment instrument- the Withdrawal
  2 
Assessment Tool (WAT-1)7 been developed and this tool is reviewed in Chapter 2. In 
addition, only one study conducted in an adult and pediatric population analyzed the 
effect of use of an opioid taper algorithm on occurrence and nature of opioid withdrawal 
symptoms. Once clinicians can recognize risk factors for opioid withdrawal and can 
appropriately assess their patients using a validated opioid withdrawal instrument, the 
goal of tapering an opioid properly while avoiding opioid withdrawal is possible. 
Although the WAT-1 was published in 20087, except for the initial and 
subsequent validation studies for the WAT-1, no studies have been conducted using a 
validated pediatric opioid withdrawal assessment tool to describe the frequency of 
opioid withdrawal as well as factors that affect the frequency. Since little information is 
known about opioid withdrawal in a pediatric population, a study describing the 
frequency of opioid withdrawal signs and symptoms and to identify factors associated 
with opioid withdrawal is presented in Chapter 3. 
A prospective, longitudinal descriptive study was initiated to explore the 
frequency of opioid withdrawal and detect associated risk factors in a pediatric 
population. The specific aims of this study were to: (1) describe the signs and symptoms 
of opioid withdrawal in children undergoing opioid tapering; and (2) examine the 
relationship among opioid withdrawal signs and symptoms, opioid exposure (cumulative 
opioid dose, peak opioid dose, duration of opioid exposure), opioid taper rate and the 
child’s age. Permission for inclusion in the study was obtained from parents or legal 
guardians. Twenty six participants were enrolled. Demographic data was collected to 
describe the sample. To identify opioid withdrawal signs and symptoms, the WAT-17 
was used daily. Opioid exposure prior to study enrollment was calculated and all opioids 
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converted to morphine equivalents. Each day’s previous twenty-four hours opioid 
exposure was calculated and converted to morphine equivalents per kilogram (MEK). 
All participants were assessed for opioid withdrawal daily for up to 7 days. Participant 
characteristics were examined for possible association with opioid withdrawal.  
On any given day, opioid withdrawal was noted in half (n=12) of the participants. 
The most common signs of opioid withdrawal were diarrhea, vomiting, sweating and 
fever. Of those participants who had opioid withdrawal, the level of severity, based on 
WAT-1 scores, was not severe. In addition, for those patients with opioid withdrawal, the 
effect of previously reported risk factors was examined. There was no relationship 
between peak opioid dose and opioid withdrawal. We found a relationship between 
opioid duration and withdrawal that approached significance (r=0.36; p-value>0.07), 
showing that as opioid duration increased, opioid withdrawal increased. In addition, as 
cumulative opioid dose increased, withdrawal increased (r=33; p>0.09). 
This study contributes new knowledge to the description of signs and symptoms 
of opioid withdrawal in the pediatric patient undergoing opioid tapering. We believe this 
is the first study to be conducted using the WAT-1 to measure signs and symptoms of 
opioid withdrawal in children. The investigators who developed and validated the WAT-1 
found that opioid duration and cumulative dose were predictors of risk of opioid 
withdrawal. In conjunction with the evidence reported by the investigators who 
developed and validated the WAT-1 scale, this evidence should inform clinicians of the 
potential risk factors as well as signs and symptoms of opioid withdrawal in children. 
Improvements in opioid management may lead to higher patient satisfaction, decreased 
length of stay and decreased suffering.  
  4 
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CHAPTER 2. OPIOID TAPERING IN CHILDREN: 
A REVIEW OF THE LITERATURE 
 
Background 
Routine sedation and analgesia for ventilated children in the intensive care unit is 
standard practice. Unfortunately, the therapeutic goal of providing adequate analgesia 
and sedation often results in days to weeks of continuous exposure to opioids and 
sedatives. Continuous exposure results in iatrogenic opioid and sedative dependence. 
In children, physical dependence has been found to occur in as little as two to three 
days of continuous opioid therapy.1 Tolerance to opioids has been seen to develop 
even more rapidly in neonates and infants.2  Once the child no longer needs the opioid 
or sedatives, the medications are weaned. Since tapering routines vary among 
practitioners, it is not uncommon for nurses to witness symptoms of opioid withdrawal in 
this vulnerable population. Opioid withdrawal symptoms include hiccups, goose bumps, 
chills, fever, tachycardia, tachypnea, hypertension, agitation, restlessness, insomnia, 
nausea, vomiting, diarrhea, cramps, lacrimation, rhinorrhea, yawning, diaphoresis, 
mydriasis, bone pain, muscle aches and spasms, and seizures.1 Acute effects of 
withdrawal symptoms are numerous. Diarrhea and vomiting can lead to dehydration. 
Tachycardia may lead to unnecessary IV fluid boluses or even cardiology evaluations. 
Routine use of validated opioid withdrawal assessment tools or algorithms is rare, which 
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contributes to delays in diagnosis of opioid withdrawal syndrome and proper treatment. 
Potential long term effects of poorly managed withdrawal symptoms are unknown; 
however, possible consequences include prolonged tapering duration in response to 
attempts to alleviate withdrawal symptoms as well as needless physical and emotional 
suffering. Of note, only one position statement on drug withdrawal was discovered 
during the search. The American Academy of Pediatrics (AAP) has a position statement 
on neonatal drug withdrawal with recommendations that include multimodal maternal 
screening for opioid use, enhanced recognition of signs of opioid withdrawal, routine 
use of appropriate opioid withdrawal tools, and medication recommendations for opioid 
or sedative withdrawal.3 However, no such statement exists for the pediatric population.  
The purpose of this critical review of the literature was to synthesize and critically 
analyze published research and other critical reviews on opioid withdrawal management 
in children. 
METHODS 
A search of the major databases for English language publications included 
Cochrane, MEDLINE, CINAHL and PsychInfo. Keywords used included: “opioid”, 
“withdrawal”, “abstinence”, “infant” and “child” (n=114). The resulting group was then 
limited to 1980-2009 (n=93). Age limits were set at one month to eighteen years of age. 
Even though there is a wealth of information regarding opioid abstinence syndrome in 
neonates, studies pertaining to premature neonates or infants born to mothers on 
opioids were excluded due to the neurodevelopmental differences in manifestations of 
opioid abstinence syndrome. Two articles were excluded since they were inaccessible. 
The remaining articles were reviewed for relevance to the purpose of the review (n=20). 
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Articles were included if the focus remained on a pediatric population undergoing opioid 
tapering. Due to the relatively small sample size, articles that included a mix of pediatric 
patients and adult patients were included. Opinions, editorials and individual case 
studies were not included. In addition, articles that studied the efficacy of a prophylactic 
pharmaceutical intervention were excluded. The remaining articles were assessed for 
inclusion criteria. Thirteen papers met the criteria for review. 
DATA COLLECTION AND ANALYSIS 
 Once accepted for review, the main aspects of each article were extracted and 
summarized in table format. These thirteen papers were categorized into five groups 
determined by the main focus of the research:  opioid tolerance in children (n=1); 
incidence of opioid withdrawal (n=6); review articles (n=2); use of algorithm or protocol 
(n=1); validation of assessment tools in pediatric population (n=3). The table was further 
delineated into five columns: year, authors, sample, design and key findings. (See Table 
1)  Conclusions from each of the articles were reviewed and examined for emerging 
themes. Upon completion of tabulation, findings were reviewed and assessed for 
correlations and similarities. 
RESULTS 
Opioid tolerance in children. Only one study was found that reviewed opioid 
tolerance in children and infants.4 Scales reviewed were all validated in neonatal 
populations. The authors concluded that opioid withdrawal could be avoided with the 
use of appropriate tapering protocols and assessment tools. Should signs of withdrawal 
occur, pharmacological and non-pharmacological interventions were suggested. Non-
pharmacological intervention suggestions included rocking, swaddling, reduced 
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environmental stimulation and frequent feedings. Pharmacological recommendations for 
length of taper correlated with length of exposure to opioids. Specifically, if opioid 
exposure was less than one week, tapering could occur over three days. For infants 
exposed to over one week of opioids, a less aggressive protocol, tapering over two to 
three weeks, was recommended. 
Opioid withdrawal symptoms in children. Six studies examined the incidence of 
opioid withdrawal symptoms in children undergoing opioid taper. All but one of the 
studies was conducted in a pediatric intensive care unit (PICU). Katz, Kelly and His 
examined the occurrence of opioid withdrawal in critically ill children who had received 
continuous infusion fentanyl for greater than twenty-four hours.5 Using the Neonatal 
Abstinence Scoring Scale (NAS) on a population (n=23) of children ranging in age from 
one week to twenty-two months, they found a high incidence of opioid withdrawal that 
was both dose and duration dependent. It should be noted that the practitioners used a 
very aggressive weaning regimen entailing a dose reduction of fifty percent each day for 
two days and then discontinuation of the opioid on day three. Subsequent research has 
found that this type of rapid taper, which was the norm at the time, invariably results in 
withdrawal. A few years later, Carnevale and Ducharme conducted an observational 
study to examine adverse reactions to opioid and benzodiazepine withdrawal in critically 
ill children.6 Although their study was limited by the small sample size (n=5) and the lack 
of a validated assessment tool, the resulting observations of relationships between 
types of behavioral symptoms across a variety of clinical contexts did contribute to the 
generalizability of opioid withdrawal symptoms over multiple patient populations. In 
2005, the same authors used a prospective multiple case study design to observe the 
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effects of variable weaning rates on incidence of opioid and benzodiazepine withdrawal 
symptoms.7  The pediatric intensive care unit patients (n=27) ranged in age from one 
month to nineteen years. Again, the authors used a relatively small sample size and did 
not use a validated assessment tool and instead relied on data collection gleaned from 
nurses’ notes. Despite these limitations, the authors did note the need to tailor the 
percentage of wean to the length of time on opioids. Pederson and Parran used a daily 
patient self-report log on a post hematopoietic cell transplant cohort of patients ranging 
in age from seven to sixty-four years and found that the length of taper needed to avoid 
withdrawal symptoms correlated with both pretaper opioid dosage and length of 
pretaper opioid therapy.8 Furthermore, withdrawal symptoms were highest on taper 
days two through six. In a prospective repeated measures design study using the 
Sophia Benzodiazepine and Opioid Withdrawal Checklist (SBOWC), Ista and 
colleagues found that the most common symptoms of opioid withdrawal in children 
ranging in age from zero days to sixteen years (n=79) included sleeplessness, 
increased temperature, diarrhea, tremors and pupil dilation.9 Only one randomized 
double blinded trial was found.10 PICU patients (n= 37) with an average age of nine 
years were randomized to a five or ten day weaning protocol with both groups receiving 
enteral methadone. The authors found no significant difference between the five day 
and ten day wean groups. Limitations of this study include the small sample size and 
the use of an assessment tool (NAS) only validated for assessment of neonatal 
abstinence. 
Opioid withdrawal review articles. Due to the paucity of articles related to 
pediatric opioid withdrawal, two review articles were included. Ista and colleagues 
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published a literature review with similar recommendations to employ strategies to 
decrease the amount of opioid administered.11 Since the majority of studies conducted 
on children used assessment tools validated in a neonatal population they may have 
produced unreliable results. The authors conclude that an appropriate assessment tool 
for use in the pediatric population is sorely needed. During the same year, Bartolome 
and colleagues published a literature review with the intent of gleaning analgesia and 
sedation management recommendations from the existing body of evidence.12  As with 
the Ista group, the authors found many gaps in the existing literature including the 
existence of an appropriate assessment tool to facilitate avoidance of adverse effects 
such as opioid withdrawal. 
Opioid withdrawal assessment tools for children. Only two studies attempted to 
develop an opioid withdrawal tool for children. 13, 14 Both tools were developed by the 
same team of researchers. In fact, the latter tool is merely a revision of the first tool. The 
Opioid Benzodiazepine Withdrawal Scale (OBWS), a 21 item assessment instrument, 
was tested in PICU patients who were undergoing opioid and benzodiazepine tapering. 
Out of fifteen patients, thirteen experienced symptoms of withdrawal despite the use of 
a tapering protocol and the OBWS. The most common symptoms witnessed were 
sleeplessness, tremors, mydriasis and diarrhea and occurred as late as six days after a 
greater than ten percent taper in opioid. Initial psychometrics were adequate, but could 
be improved (sensitivity= 0.50; specificity=0.87). A subsequent multicenter prospective 
repeated measures study assessing the predictive validity of a newly revised nineteen 
item scale ensued. The resulting Withdrawal Assessment Tool-1 (WAT-1) effectively 
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replaces the first tool with its far superior psychometric performance (sensitivity= 0.872; 
specificity=0.88).14  
One study developed an opioid and benzodiazepine withdrawal scale for 
children. The Sophia Observation Withdrawal Symptoms scale (SOS) is a 15 item scale 
that takes into account the overlap of opioid and benzodiazepine symptoms of 
withdrawal.15  In comparison to the WAT-1 (7 minutes), the SOS takes a mere 2 
minutes to complete. 
Algorithms or protocols for opioid weaning. Within all of the included articles, the 
authors allude to varying opioid tapering practices (Table 2). Only one study used an 
assessment based tapering algorithm. Parran and Pederson conducted a quasi-
experimental study that tested the impact of use of an opioid tapering algorithm on the 
incidence of opioid withdrawal symptoms.16  Their study included 106 patients who were 
one month post hematopoietic cell transplant. The ages of participants ranged from 5 to 
64 years. The authors concluded that the total reports of withdrawal symptoms 
positively correlated with length of taper (r=0.46, p<0.001). That is, with a longer taper, 
there were fewer symptoms of withdrawal. Overall, the results indicated a decrease in 
incidence of opioid withdrawal symptoms for those patients who were tapered with use 
of the opioid taper algorithm.  
Conclusions 
Implications for Practice. This review supports the need for a pediatric opioid 
withdrawal assessment tool with excellent psychometric properties that can be used in a 
variety of settings. The WAT-1 instrument certainly appears promising. Since the 
majority of PICUs routinely use a combination of benzodiazepines and opioids for 
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sedation and analgesia, the recently published development of the SOS scale, with its 
short application time and attention to both opioid and benzodiazepine withdrawal 
symptoms, merits a deserved second glance. Several studies demonstrated the need 
for adherence to a dose and duration dependent tapering protocol with ongoing 
assessment and reassessment for withdrawal symptoms.  
Multiple opportunities abound for the advanced practice nurse to positively 
influence practice and outcomes. In order to avoid immediate and potentially long term 
harm, the advanced practice nurse can lead the development of evidence based 
practice guidelines for opioid tapering in the pediatric population. By using the 
information drawn from a validated opioid withdrawal assessment tool to guide practice, 
the advance practice nurse has the ability to individualize the opioid tapering plan for 
each child. Besides the obvious ethical implications of prevention and treatment of 
suffering, the advanced practice nurse has the ability to contribute to the overall care of 
the patient by providing optimal symptom management and efficient, assessment based 
opioid tapering. As we enter into an era of ever increasing restrictions on the provision 
of and reimbursement for health care, the advanced practice nurse is in an ideal 
position to guide care with a goal of prevention of unnecessarily lengthy 
hospitalizations. Overall, the efficacy of an assessment-based opioid tapering regimen 
may result in improved patient outcomes, greater provider satisfaction and confidence, 
enhanced family satisfaction and potential cost savings.  
Implications for Research. With the advent of validated, pediatric-specific, opioid 
withdrawal instruments, opportunities abound for future research. Further research is 
needed to test the WAT-1 and SOS tools in settings outside of the PICU. Replicative 
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studies are now possible substituting an appropriate assessment instrument for the 
pediatric population such as the WAT-1 or the SOS for the NAS. Although the focus of 
the majority of the studies was the incidence of withdrawal symptoms experienced by 
the children, the tapering protocol used for and during the studies provides guidance for 
the future development of an evidence-based tapering algorithm. Additional studies of 
importance include evaluation of improved outcomes such as decreased length of stay, 
decreased length of taper, and avoidance of unnecessary diagnostic testing secondary 
to enhanced capability to accurately assess and diagnose withdrawal. 
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Table 1. Studies Included in Critical Review  
Year Authors Sample 
 (age) 
Design Key Findings 
1994 Anand & Arnold NA Literature Review NAS preferred 
1994 Katz, Kelly & 
His 
23  
(1 wk-22m) 
Prospective, case 
series 
 withdrawal seen in >5 days 
duration of therapy 
1997 Carnevale & 
Ducharme 
5  
(2m-16m) 
Prospective, 
multiple case study 
inconsolable crying, tremors, 
jitteriness, irritability, gagging, 
vomiting & feeding problems 
< 24 hr post wean 
2000 Pederson & 
Parran 
45 
(7-64 yrs) 
Prospective, 
descriptive 
Withdrawal symptoms highest on 
taper days 2 through 6 
Length of taper correlated with both 
pretaper opioid dosage & length of 
pretaper opioid therapy. 
2002 Parran & 
Pederson 
106 
(5-64 yrs) 
Quasi-experimental Positive relationship between 
length of taper & total reports of 
withdrawal symptoms (r= 0.46, 
p<0.001) 
2004 Franck et al. 15 
(6wks – 
28m) 
Prospective, 
repeated measures 
OBWS developed 
Sensitivity = 0.50 
Specificity = 0.87 
2005 Berens, et al. 37 
(36 wks – 
18yr) 
Prospective, 
randomized double 
blind methadone 
wean 
No difference in withdrawal 
between 5 day or 10 day 
methadone wean 
2005 Ducharme et al. 27 
(1m- 19 yr) 
Prospective, 
multiple case study 
Final weaning recommendations: 
1-3 day= 20% wean per day 
4-5d= <20% wean per day 
6-7d= 13% wean per day 
8-14d= 8-13% wean per day 
15-21d= <8% wean per day 
>21d= 3% wean per day 
2007 Bertolome, Cid 
& Freddi 
NA Literature review Lack of individualized tapering 
regimens 
2007 Ista et al. NA Literature review Overlap of withdrawal symptoms 
for opioids & benzodiazepines 
2008 Franck et al. 83 Multi-centered 
prospective 
psychometric 
evaluation 
OBWS revised to create WAT-1 
WAT-1 validated 
Sensitivity = 0.87 
Specificity = 0.88 
2008 Ista et al. 79 
(0-16 yrs) 
Prospective, 
repeated measures 
Most frequent symptoms= 
Sleeplessness, temp, diarrhea, 
tremors & pupil dilation 
2009 Ista et al. 79 
(0-16 yrs) 
Instrument 
validation 
SOS developed 
 d=day; m= month; NA= non-applicable; NAS= Neonatal Abstinence Score; OBWS= Opioid 
Benzodiazepine Withdrawal Scale; SOS= Sophia Observation withdrawal Symptoms scale; 
wk=week; WAT-1= Withdrawal Assessment Tool; = increased 
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 Table 2. Summary Tapering Techniques During Opioid Weaning 
Year Authors N Age Opioid (O) 
or  
Benzo (B)  
Assessment 
Tool 
Tapering 
Technique 
Incidence 
of 
Withdrawal 
Symptoms 
1994  Katz, Kelly 
& His 
23 < 2 
years 
Fentanyl NAS Fentanyl weaned  
50% every 24h 
57% 
1997 Carnevale 
& 
Ducharme 
5 2m -
16m 
O & B No tool sited >25% to 50% within 
24 hours  
100% 
2002 Parran & 
Pederson 
106 5-64 
years 
O 0-10  or 
FACES 
14 symptom 
withdrawal log 
Interview  
Medication 
Profile 
Algorithm 16% 
2004 Franck et 
al. 
15 6wk – 
28m 
O & B OBWS 
Nurses’ clinical            
judgement 
Medical record 
review 
>14 days  = 10% 
daily  
> 5 days = 20%  
daily  
 
87% 
2005 Ducharme 27 0 – 19 
yrs 
O & / or B Nurses’ notes Duration of 
exposure 
(recommended 
daily wean) 
a) 1-3 days (20%) 
b)  4-7 days (13-
20%) 
c)  8-14 days (8-
13%) 
d)  15-21 days 
(<8%) 
e) > 21 days (3%) 
NA 
2008 Ista et al. 79 0-16 
yrs 
O & B SBOWC  morphine by 10 
g/kg/hr every 24h; 
 midazolam 
50g/kg/hr per 8 
hrs 
34% 
Benzo = benzodiazepine; hr = hour; hrs= hours; kg= kilogram; g = microgram; m= month; N= 
sample size; OBWS = Opioid Benzodiazepine Withdrawal Scale; SBOWC= Sophia 
Benzodiazepine and Opioid Withdrawal Checklist; NAS= Neonatal Abstinence Scoring System ; 
wk= week;  yrs=years; ↓= decrease 
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CHAPTER 3. OPIOID WITHDRAWAL SIGNS AND SYMPTOMS IN CHILDREN: 
  FREQUENCY AND DETERMINANTS 
 
INTRODUCTION 
Over 90% of critically ill children receive opioids.2 Routine use of analgesia and 
sedation for critically ill, ventilated children is essential for the child’s comfort and safety 
and to protect the child from self-harm due to unplanned endotracheal extubation, 
anxiety related increased oxygen demand and ventilator dysynchrony.8 However the 
therapeutic goal of providing adequate analgesia and sedation often results in days to 
weeks of continuous exposure to opioids and sedatives. Continuous exposure may 
result in iatrogenic opioid and sedative dependence. Opioid dependence is defined as a 
state of adaptation that is manifested by a drug class specific withdrawal syndrome that 
can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of 
the drug, and/or administration of an antagonist.4 Opioid tolerance is defined as a state 
of adaptation in which exposure to a drug induces changes that result in a diminution of 
one or more of the drug's effects over time.4 Once the child no longer needs the opioid 
or sedative, the medications are reduced over time. The goal of tapering is to safely 
wean the opioid dose while avoiding opioid withdrawal. Opioid withdrawal refers to signs 
and symptoms that occur following an abrupt discontinuation or rapid decrease in an 
opioid after opioid dependence has developed. Unfortunately, there is little empirical 
evidence to guide the practice of opioid tapering.3,9,10 Since opioid tapering practices 
vary among practitioners, it is not uncommon for nurses to witness signs and symptoms 
of withdrawal in this vulnerable population. Opioid withdrawal signs and symptoms in 
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children include diarrhea, nausea, vomiting, fever, sweating, mottling, tremor, agitation, 
frequent yawning, frequent sneezing, motor disturbance, insomnia and hypertonia.1,3,7,9-
19 
Few data have been published on the incidence of opioid withdrawal in the 
pediatric population with the reported incidence of opioid withdrawal varying widely (0-
100%).1,9,11,20 In addition, studies of opioid withdrawal conducted in the pediatric 
population have used neonatal withdrawal tools1,9,11,20-22 or no opioid assessment tool.9-
12 The use of developmentally inappropriate tools such as neonatal opioid withdrawal 
tools may result in conclusions that are flawed. In 2008, Franck et al. developed the 
Withdrawal Assessment Tool-1 (WAT-1) (Fig 1), a pediatric opioid withdrawal scale.3,10 
Presently, the WAT-1 is the only validated pediatric opioid withdrawal assessment tool. 
Although another tool, the Sophia Observation withdrawal Symptoms scale (SOS), has 
also been developed, its psychometric properties have yet to be published.13 Except for 
the initial and subsequent tool validation studies of the WAT-1, no studies have been 
conducted to identify the incidence of pediatric opioid withdrawal using a validated 
pediatric opioid withdrawal assessment tool.7,23 In addition there are few data about 
factors that may affect the frequency of withdrawal signs and symptoms including opioid 
exposure (cumulative opioid dose, peak opioid dose, duration of opioid exposure), 
opioid taper rate, and the child’s age.1,3,7,9-14,16-21,24 Further, PICU length of stay (LOS)7, 
duration of mechanical ventilation (LOMV) and cumulative opioid dosage (mg/kg) are 
positively associated with signs and symptoms of opioid withdrawal.7,19,20 Although 
associations among opioid duration9,17,20,21 and cumulative dose20,21 prior to taper and 
occurrence of opioid withdrawal signs and symptoms have been identified, data 
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concerning other factors (peak opioid dose9, opioid taper rate and age7) that may affect 
opioid withdrawal signs and symptoms are limited.  
Although pediatric guidelines for opioid tapering exist, they are based on little 
empiric evidence.1,9,25,18,25 In order to describe present opioid tapering practices by 
pediatric practitioners, we conducted a cross-sectional web based survey14 using 
international pediatric pain and palliative care email list serves. Of the 104 respondents, 
only 22 (27%) had a written protocol for opioid tapering. Respondents without a protocol 
reported regimens for opioid withdrawal that varied greatly. In addition, only half of the 
respondents (n=52) used an opioid withdrawal assessment tool. Of those using an 
assessment tool, the majority used the WAT-1 (n=22) followed by the Finnegan 
Neonatal Abstinence Score (NAS) (n=14).14 
This study will investigate the incidence of opioid withdrawal and factors 
associated with development of opioid withdrawal in a pediatric population. More 
importantly, our study will measure opioid withdrawal using a validated, pediatric tool – 
the WAT-1. Accurate assessment of opioid withdrawal is important for several reasons. 
The acute effects of withdrawal not only result in discomfort but can be dangerous as 
well. Diarrhea and vomiting can lead to dehydration and tachycardia may lead to 
unnecessary intravenous fluid resuscitation or cardiology evaluations. Poorly managed 
signs and symptoms of opioid withdrawal may lead to prolonged LOS.  
Therefore, the purpose of this study is to describe the frequency of opioid withdrawal 
signs and symptoms and to identify factors associated with these opioid withdrawal 
signs and symptoms. The specific aims of this study are to (1) describe the signs and 
symptoms (WAT-1) of opioid withdrawal in children undergoing opioid tapering and (2) 
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examine the relationship among opioid withdrawal signs and symptoms (WAT-1), opioid 
exposure (cumulative opioid dose, peak opioid dose, duration of opioid exposure), 
opioid taper rate, and the child’s age. 
METHODS 
Setting and Sample 
The study was conducted in the Pediatric Intensive Care Unit (PICU), the 
Pediatric Progressive Care Unit (PPCU) and the acute care pediatric units at the 
Children’s Hospital of Richmond, Virginia Commonwealth University Health Systems 
(VCUHS). The PICU, the PPCU and acute care areas, admit children with a wide range 
of pediatric diagnoses enhancing generalizability of study findings. 
The sample of 26 were drawn from all patients, ages 2 weeks to 21 years, 
admitted to the PICU who had received continuous or scheduled infusion opioids for 
greater than 5 days.1,7,17,20 Previous studies have found that opioid tolerance may occur 
after 5 days of opioid exposure18,20,26 and that opioid withdrawal signs and symptoms 
are highest during taper days 1 through 6. Therefore children were enrolled in the study 
and data collection occurred daily up to 7 days.3,11,12,21,27 Pediatric patients (2 weeks to 
21 years) from all ethnic and racial backgrounds were recruited. Since restlessness is 
part of the WAT-1 evaluation, children with paralysis of one or more limbs or who were 
receiving neuroparalytics were excluded.   
Measurement of Key Variables 
Opioid Withdrawal Signs and Symptoms. Opioid withdrawal signs and symptoms 
were measured using the 11 item Withdrawal Assessment Tool – 1(WAT-1) (Fig 1). The 
WAT-1 is a pediatric opioid withdrawal tool that evaluates three categories of symptoms 
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with symptom scores ranging from either 0-1 or 0-2 based on the type of symptom and 
its severity. It includes measures of gastrointestinal symptoms (diarrhea, nausea, 
vomiting), autonomic (fever, sweating) and central nervous system (tremor, sedation 
state, uncoordinated movement, yawning or sneezing, startle to touch, muscle tone and 
time to gain calm) signs and symptoms of opioid withdrawal.7 The 19 item WAT-1 was 
tested in a pediatric critical care population (n=83; 1040 observations) ranging in age 
from 6 months to 10 years. Redundant signs and symptoms and symptoms with low 
levels of association with withdrawal intensity ratings were eliminated resulting in the 
current recommended 11 item (12 point) tool. The original validity and reliability testing 
revealed high sensitivity (0.87) and specificity (0.88). Further psychometric evaluation of 
the tool was conducted in a multicenter prospective repeated measures design study 
which included pediatric critical care and general care patients (n=126; 836 
observations).23 The WAT-1 has four steps. First, the previous 12 hours are reviewed 
for stooling, vomiting and fever. Second, the subject is observed for 2 minutes prior to 
any stimulus for behavior state, tremor, sweating, uncoordinated movement, yawning 
and sneezing. Third, a 1-minute progressive stimulus is used to assess startle to touch 
and muscle tone and fourth, a post stimulus observation is used to assess time to gain 
calm. Total WAT-1 scores range from 0-12 and a score of 3 or greater indicates 
presence of opioid withdrawal.7 
Opioid Exposure. Withdrawal signs and symptoms may be affected by both the 
opioid cumulative and peak dose administered during opioid therapy. Therefore opioid 
exposure will include these variables as well as opioid duration. Previous studies have 
shown that the duration of opioid receptor occupancy is related to the development of 
  28 
opioid tolerance.3,22,28,29 In a prospective study conducted by Katz et al. (1994), 23 
infants (<23 months) were observed for signs of opioid withdrawal post opioid exposure 
using the Neonatal Abstinence Scale, an tool designed for the neonatal population.20 
They found a positive correlation of dosage (p<0.005) and length of exposure 
(p<0.0001) with opioid withdrawal symptoms. In fact, a cumulative dose of 2.5mg/kg 
fentanyl or more than 9 days exposure was 100% predictive of withdrawal. Although the 
results of these studies are compelling, study limitations, including small sample size, 
narrow age range and use of a developmentally inappropriate tool may affect 
generalization to the pediatric population. Further, the relationship between peak opioid 
dose and opioid withdrawal is limited to one study.9 In a prospective study of critically ill 
children (n=27), Ducharme et al.9 found a significant relationship (r=0.34; p<0.05) 
between peak opioid dose and opioid withdrawal. However, opioid withdrawal was 
measured indirectly by reviewing nurses’ documentation. 
Opioid Dose. Several previous studies have found a relationship between 
cumulative opioid dose and opioid withdrawal although most have been either 
conducted in infants only or in pediatrics using a measurement tool designed for infants. 
In one of the first studies to investigate the relationship between potential risk factors 
(opioid exposure and withdrawal) using a prospective study of infants ranging in age 
from 1 week to 22 months, Katz et al. found that a total dose of 1.5mg/kg was 
associated with a 50% rate of opioid withdrawal.20 Other studies conducted in children 
have found a similar dose dependent relationship.9,21,26  In a prospective, multiple case 
study (n=27), Ducharme and colleagues examined the effects of variable opioid taper 
rates on occurrence of opioid withdrawal on PICU patients (age 0-19 years). They found 
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a small but significant association between opioid peak dose and occurrence of 
withdrawal (r=0.34; p<0.05).9 One opioid specific study examined the relationship 
between fentanyl, the preferred opioid in pediatric critical care, and opioid withdrawal. In 
this prospective, descriptive opioid withdrawal study of critically ill infants and young 
children (< 25 months), French and Nocera found a strong correlation between 
cumulative fentanyl dose and opioid withdrawal score (r=0.76; p<0.01).21 Likewise, in a 
retrospective study of neonates, Arnold and colleagues found a total dose of 1.6mg/kg 
to be associated with the development of opioid withdrawal.26 However all of the results 
described here are limited by narrow age range of the study populations, small sample 
sizes and the use of opioid withdrawal assessment tools designed for neonates in an 
older population. Because the literature shows a relationship between cumulative and 
peak opioid dose on occurrence of opioid withdrawal opioid withdrawal, opioid dose was 
described as both cumulative and peak.9,20,21,26 
To compare analgesics across types, all opioids were converted to morphine and 
reported as morphine equivalents per kilogram (MEK).12,17 For this study, fentanyl 
conversion to morphine was calculated by the formula 10mg of IV morphine = 0.1mg IV 
fentanyl.30 Daily dose of MEK was calculated. Peak and cumulative MEK were 
calculated pretaper and daily during taper. The largest daily MEK was recorded as the 
peak opioid dose. Cumulative dose was determined by summation of daily MEKs prior 
to initiation of opioid taper.  
Opioid Duration. Previous studies have found that duration of opioid exposure 
effects opioid withdrawal. Ducharme and colleagues found a moderate association 
between opioid duration and occurrence of opioid withdrawal (r=0.41; p<0.01).9 Katz et 
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al. found that a duration of 5 days or more of fentanyl exposure was 50% predictive of 
opioid withdrawal.20 French and Nocera found a significant correlation between duration 
of fentanyl exposure and opioid withdrawal score (r=0.70; p<0.05).21  In a prospective, 
repeated measures design study of critically ill children (n=79; ages 0 to 16 years), Ista 
and colleagues found a significant correlation between duration of opioid exposure and 
severity of opioid withdrawal (r=0.52; p<0.001).17 In this study opioid duration was 
calculated as the number of days of continuous or scheduled opioid exposure prior to 
initiating opioid taper. Only children with at least 5 days of opioid exposure were eligible 
for the study. 
Opioid Taper Rate. Although opioid tapering recommendations exist in the 
literature, few are based on empiric evidence.1,9,18,25,31 Since rates of taper vary 
depending on clinician, opioid tapering rate was defined as dose change per day, 
expressed in morphine equivalent units per kilogram (MEK) of the child’s body weight. 
Nonscheduled opioids that were administered were included in the daily opioid tapering 
rate calculation. The MEK/day was compared to the previous day’s MEK/day dose. In 
addition, medications that may alleviate withdrawal signs and symptoms such as 
benzodiazepines, -adrenergic (clonidine, dexmedetomedine), antiemetics and 
antipyretics were recorded. 
Procedures 
Prior to beginning the study, an informational in-service was provided to the 
pediatric nursing leadership and staff of the involved units. The study was approved by 
the VCU Institutional Review Board at VCU and included waiver of assent since the 
pediatric participants were sedated during the observation period. Permission was 
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obtained from the parent/legal guardian at time of study enrollment. Patients who met 
selection criteria were identified through daily PICU rounds. Data obtained did not affect 
the participant’s routine care nor was it used in the clinical management of opioid 
tapering.  
Data collection timing occurred daily, for up to 7 days, between 10 AM and 4 PM 
during times of routine care in order to allow a consistent time point from the previous 
day’s opioid dosing changes and avoid the usually busy early morning clinical rounds. 
The exact time was negotiated with the bedside nurse in order to minimize any potential 
disruption of routine care. At the time of study enrollment, the following data from the 
electronic medical record (EMR) and bedside flow sheet were collected: medications 
received within the past 24 hours, data to calculate opioid cumulative dose (in MEK) 
peak opioid dose (in MEK), and number of days of opioid exposure prior to study 
enrollment demographic data (age, race, gender, admission diagnosis, weight in 
kilograms). 
Data collection for the opioid taper rate occurred each day for up to 7 days. We 
collected opioid dose information given over the past 24 hours (8a to 8a). All opioids 
were converted to MEK. The sum of the MEKs was recorded as the MEK/day. 
Data collection for the WAT-1(Fig1) began with a review of the EMR and flow 
sheet for the previous 12 hours followed by direct observation for 2 minutes and then a 
1 minute progressive stimulus observation. During the direct observation data was 
collected on state, tremor, sweating, uncoordinated/repetitive movements and yawning 
or sneezing. Next, the patient was observed during the1 minute progressive stimulus. 
During the 1 minute progressive stimulus observation, data on muscle tone and startle 
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to touch was collected. Finally, the patient was observed for up to 5 minutes to assess 
time to recovery post stimulus. The WAT-1 was measured daily for up to 7 days. With 
the exception of 4 observations, all WAT-1 measurements were collected by the same 
investigator. Training for the second evaluator consisted of didactic review of the tool 
and its use followed by simultaneous WAT-1 assessments with the primary investigator. 
Once agreement was met on how to use the WAT-1, the second investigator was 
allowed to obtain data independently using the WAT-1. 
Data Analysis 
Demographic variables were summarized and measures of central tendency 
(mean, median) and dispersion (standard deviation, range) were calculated on 
continuous data, and frequency and counts were computed on categorical data. 
Descriptive statistics (means and standard deviations) were used to address the 
first study aim. Individual variable scores and total WAT-1 scores were recorded. For 
the second aim distributions of all study variables were examined to determine the need 
for transformations. The opioid duration and cumulative opioid dose data were skewed 
therefore log transformations were done to stabilize the variance and make the 
distributions more normal. These transformed values were used in all analyses. 
Correlational analyses were used to examine the relationship among opioid withdrawal 
signs and symptoms (WAT-1), and opioid tapering rate, opioid exposure (log cumulative 
opioid dose, peak opioid dose, log duration of opioid exposure), and the child’s age. 
Plots were produced to describe the change in individual symptoms over time and the 
relationship between average opioid dose and average total WAT-1 score over time. 
Mixed effect repeated models were used to determine if the changes in the WAT-1 
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score over study days 1 to 7 were due to 1) log opioid duration, 2) log cumulative opioid 
dose, 3) age, 4) gender, 5) race, 6) LOMV and 7) ICU LOS. For every comparison 
performed in this study, the significance level was set at p<0.05. 
RESULTS 
Participants 
Twenty-eight patients met inclusion criteria. Since two families declined 
participation, twenty-six (93% of those eligible) were enrolled in the study. One 
participant who was on Extracorporeal Membrane Oxygenation (ECMO) was excluded 
at analysis due to his extreme cumulative opioid dose (10 fold increase over next 
largest value) and potentially confounding severity of illness. Thus the twenty-five 
participants had a mean age of 6.7 years (79.8 months) and were primarily male and 
white (Table 1). The majority (n=21) were enrolled from the Pediatric Intensive Care 
Unit and respiratory illness, trauma and post-operative management were the most 
common admission diagnoses. Most (n=19) were ventilated and the median duration of 
mechanical ventilation for those ventilated was 8.5 days (IQR=5 – 18.5 days) (Table 1). 
Median length of opioid duration was 8 days (IQR=5 – 15.5 days) (Table 3). Opioid 
taper rates varied widely from an average daily dose reduction of 24.4 MEK between 
observation days 1 and 2 to an increase of 14.05 MEK between days 1 and 2 (Table 4). 
Signs and symptoms of opioid withdrawal 
A total of 155 WAT-1 observations were performed in 25 participants over the 7 
day study period. Of the 25 participants, 18 had observations for all 7 days. No 
participant had a daily WAT-1 total score greater than 7 (possible score 0-12). For the 
25 participants 11(44%) had a WAT-1 score of greater than or equal to 3 on any given 
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day, indicating presence of opioid withdrawal. Of these 11, 6 (55%) were White and 
were males (56%). Only one participant had a rating greater than 5 (WAT-1 score =7), 
and 54% did not have opioid withdrawal (WAT-1 score < 3). 
The most common symptoms noted over all days were diarrhea (35%), sweating 
(25%) fever (21%), and vomiting (20%) (Table 2). Peak occurrence of symptoms, that 
is, highest WAT-1 score, was noted on day 2 (mean=2). The days with the least 
occurrence of symptoms were day 6 and day 7 (Table 2).   
Opioid Withdrawal, Exposure and Tapering 
The second study aim included an examination of the relationship between signs 
of opioid withdrawal and opioid exposure (opioid duration, cumulative opioid dose, peak 
opioid dose). Participant median duration of opioid exposure was 8 days and ranged 
from 5 to 15.5 days (Table 3). Eight (73%) participants with opioid withdrawal had 
longer than 9 days duration of opioid treatment prior to tapering. There was a positive 
relationship between log opioid duration and the maximum WAT-1 score that 
approached significance (r=0.38, p=0.06). Similarly, there was a positive relationship 
approaching significance between opioid duration and the average WAT-1 for days 1 
through 7 (r=0.33, p=0.10). The effect of opioid duration on the total WAT-1 was 
compared across days 1 to 7 using mixed models repeated measures ANOVA and no 
significant differences among the days were found (F(1,24)=2.46; p=0.13). Median 
cumulative opioid exposure was 49.12 MEK (IQR= 16.6-124.6) over time. We found that 
all (100%) participants with opioid withdrawal (WAT-1 ≥ 3) had cumulative opioid doses 
greater than 2.5 MEK. There was no relationship between the cumulative opioid dose 
and the maximum WAT-1 (r=0.29, p=0.15), or the average WAT-1 (r=0.22, p=0.28). In 
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addition, no significant differences was found between days for average WAT-1 
(F(1,25)=1.09; p=0.313). Median peak opioid exposure prior to taper was 9.8 MEK 
(IQR=16.6-124.6). Peak opioid dose was not related to the average WAT-1 (r=0.28; 
p=0.17) or the maximum WAT-1(r=0.17; p=0.42). 
Although in general a steady reduction in opioid dose during the tapering process 
is suggested, we found wide variability in opioid dose changes (tapering or increases) 
each day. Opioid dose changes included both tapering and increases in 22 (88%) 
participants over the study days. The remaining 3(12%) patients had opioid doses that 
only decreased each day (Figure 2). In addition, variability in dose was most severe 
during the first 2-3 days of the taper process, leveling off during days 4 through 7. 
Opioid Withdrawal and Other Factors  
Demographic data included gender, race, LOMV, ICU LOS and age. For these 
variables, the only effect noted was between age and peak opioid dose (r=-0.41; 
p=0.04). The effect of these variables on the total WAT-1 was compared across days 1 
to 7 using mixed models repeated measures ANOVA. There was no significant effect of 
age (F(1,23)=1.30; p=0.27), gender (F(1,24)= 0.00; p=0.99), race (F(1,24)= 2.66; 
p=0.12), ICU LOS(F(1,20)= 0.56; p=0.46) or LOMV (F(1,18)=2.42; p=0.14) on the total 
WAT-1 across days 1 to 7. 
DISCUSSION 
This prospective, descriptive observational study described the occurrence of   
signs and symptoms of opioid withdrawal in critically ill children undergoing opioid taper. 
In addition, the relationship among opioid withdrawal signs and symptoms, opioid 
exposure, opioid taper rate, and the child’s age was examined.  
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Signs and Symptoms of Opioid Withdrawal  
The most common symptoms (sweating, diarrhea, vomiting, fever) found in our 
study were similar to previous studies.3,7,13 Franck3 and Ista17 found in critically ill 
children that sleeplessness, fever, diarrhea, tremors and pupil dilation were the most 
common. Since our withdrawal tool did not include an evaluation of sleeplessness, or 
pupil dilation, comparisons to our study cannot be made. 
We found a low incidence of opioid withdrawal with only half of the sample 
having opioid withdrawal on any given day. Prior to study implementation, staff 
perception of the incidence of opioid withdrawal led us to expect a higher incidence. 
Also, our findings are lower than those noted by Frank et al.7 in the original WAT-1 
validation study (44% vs. 64%). In addition our findings showed little variability in 
severity of symptoms in those who had opioid withdrawal. That is, the level of symptoms 
was not high and very few subjects scored greater than 5 on any given day (WAT-1 
score ranges 0 to 12). Since tapering regimens often vary among practitioners14 we 
anticipated varied practice with a resulting wider range of withdrawal signs and 
symptoms in our study as well.  
Although opioid taper rate did not affect withdrawal symptoms, we found a wide 
variation in opioid tapering practice among the pediatric critical care providers at our 
institution. For example, some practitioners tapered opioid doses by 30-60% per day, 
while others used a more conservative approach (5-20% taper per day). Further, opioid 
rescue doses were not used in a consistent manner; i.e. prescribed when one or 
multiple withdrawal signs or symptoms were present; rather than using a symptom 
threshold for treatment initiation. Even though our sample differed from Franck et al.7 
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with longer durations of exposure (8 vs. 6 days) and higher peak opioid doses (9.8 MEK 
vs. 7.6 MEK), the resulting level of withdrawals symptoms was similar. Differences in 
severity of illness and opioid management may account for these findings. Individual 
practitioners may vary in their definition of optimal level of sedation and analgesia, 
opioid type and use of opioid sparing adjuvant medications. However our participants’ 
cumulative opioid dose (49.1 MEK vs. 48.2 MEK) was similar to that found by Franck et 
al.7  
Opioid Exposure 
Since withdrawal signs and symptoms may be affected by both opioid dose 
(cumulative and peak) as well as duration, we included these in our measure of opioid 
exposure. Similar to other studies, peak opioid dose did not affect opioid withdrawal. 
Previous studies have found a similar relationship between cumulative dose and opioid 
withdrawal. In a prospective study conducted by Katz et al. (1994), 23 infants (<23 
months) were observed for signs of opioid withdrawal post opioid exposure.20 They 
found the occurrence of opioid withdrawal increased as cumulative dose (p<0.005) 
length of exposure (p<0.0001) increased. Other studies conducted in children have 
found a similar dose dependent relationship.9,21,26 In a prospective, multiple case study 
(n=27), Ducharme and colleagues found, in PICU patients (age 0-19 years), that as 
opioid peak dose increases, occurrence of withdrawal also increases, although the 
association was weak (r=0.34; p<0.05).9 The majority of pediatric literature has been 
conducted in a neonatal or infant population. In a retrospective study of neonates, 
Arnold and colleagues found a cumulative dose of 1.6mg/kg or greater to be associated 
with the development of opioid withdrawal.26 Similar to others, our findings suggest that 
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as duration of exposure increases, risk of opioid withdrawal increases. However, we did 
not find a relationship between cumulative dose and opioid withdrawal. In the existing 
literature on opioid withdrawal in children, only our study and Franck’s7,23 have used a 
validated pediatric opioid withdrawal instrument. 
We found that increases in cumulative dose may also increase the potential for 
opioid withdrawal (Figure 2). Several pediatric studies had similar findings. In a 
prospective, descriptive opioid withdrawal study of critically ill children (<25 months), 
French and Nocera found a significant correlation between cumulative fentanyl dose 
(≥5.6 MEK) and opioid withdrawal score (r=0.76; p<0.01).21 Ducharme and colleagues 
found a moderate association between opioid duration and occurrence of opioid 
withdrawal (r=0.41; p<0.01).9 Katz et al. found that a duration of 5 days or more of 
fentanyl exposure was 50% predictive of opioid withdrawal.20 French and Nocera found 
a significant correlation between duration of fentanyl exposure and opioid withdrawal 
score (r=0.70; p<0.05).21 In a prospective, repeated measures design study of critically 
ill children (n=79; ages 0 to 16 years), Ista and colleagues found a significant correlation 
between duration of opioid exposure and severity of opioid withdrawal (r=0.52; 
p<0.001). Similar to our study, these researchers found a dose dependent relationship 
between duration of opioid exposure to opioid withdrawal. Our results in conjunction 
with the previous findings, lead to our recommendation of use of an assessment based 
tapering regimen for all patients deemed at risk for opioid withdrawal by nature of their 
history of duration of opioid exposure (>5days) and cumulative opioid dose (>2.5 MEK).   
Opioid taper rate 
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There is little empirical evidence to guide the practice of opioid tapering.1,9,10,20 
Although some theoretical recommendations exist in the literature,18,31 few data based 
guidelines have been tested in the pediatric population. Of those that have been tested, 
no guideline was associated with a 0% incidence of opioid withdrawal signs and 
symptoms. In this study, we found no significant relationship between opioid taper rate 
and incidence of opioid withdrawal. Given the non-linear variation in overall pattern of 
opioid taper in our patients, we were unable to detect an association between opioid 
taper rate and occurrence of opioid withdrawal. Since the majority of subjects were 
tapered using methadone, the longer and variable half-life may have confounded the 
relationship between opioid taper rate and subsequent increase in WAT-1 score.  
Age 
Given the inherent physical developmental differences in children, age-related 
differences in the incidence of opioid withdrawal may be expected. At this time, few 
studies have investigated age-related differences in the development of opioid 
withdrawal. The wide age range of our sample is similar to several previous 
studies.1,13,17 However none of these studies reported age related differences in the 
incidence or presentation of opioid withdrawal. Only Franck et al. has evaluated the 
effect of age on opioid withdrawal signs and symptoms in children.7,20 Using a sample of 
children 7 months to 10 years of age, Franck7 found a higher incidence of vomiting in 
the 0 to 2 years of age group (12.3%) compared to the >6 years age group (3.2%). In 
addition, children greater than 6 years of age (6.1%) had lower incidence of yawning 
and sneezing than the 2.1 to 6 year group (13.4%). We found no relationship between 
age and average WAT-1 score. Since the majority of the previous studies as well as this 
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study are limited by small sample sizes, the possibility that age related symptom 
differences do exist cannot be ruled out. 
Similarly to Katz et al.20, our findings revealed no association between age and 
incidence of opioid withdrawal. Although Franck found some age related differences in 
the original WAT-1 validation study7, our study did not have similar findings. Our inability 
to detect an association may be reflective of our small sample size. Studies with a larger 
sample size may more accurately reflect the developmental differences in children as 
they physically mature. Except for Ista13,17 and Franck,7,23  previous studies were limited 
by small sample sizes.  
Conclusions     
Knowledge of opioid withdrawal incidence and its related factors provides 
valuable information for proactive opioid management. For those patients with a longer 
duration of exposure, the clinician should have a heightened awareness of the potential 
for opioid withdrawal and hence the need for a tapering regimen. In conjunction with an 
appropriate tapering regimen, use of a validated pediatric opioid withdrawal tool is 
essential in the effective assessment and management of opioid withdrawal. 
Individualized, assessment based tapering regimens may lead to a shorter length of 
stay. Future evaluations of taper regimens using opioids with shorter half-lives may 
identify associations between taper rate and occurrence of opioid withdrawal. 
Inappropriate management of opioid withdrawal has the potential to increase cost due 
to use of unnecessary laboratory or radiological diagnostic testing.  
Several limitations should be considered when interpreting our findings. The 
generalizability of our findings is hampered by the small sample and use of a single site. 
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The heterogeneity of the participants’ medical conditions may have confounded our 
results. Evaluation of the effect on opioid withdrawal was limited by the low variability of 
total WAT-1 scores, which may be reflective of the unexpected conservative tapering 
practices and other medications may have interfered with appearance of opioid 
withdrawal. Further, clinicians were often aware that their patient was enrolled in the 
study, which may have led to treatment bias. In addition, since the clinicians did not 
make their treatment decisions using a validated assessment tool, the possibility of over 
diagnosis is real. The change in tapering practices styles on any given day further 
contributed to potential confounding variables for this study. Future studies evaluating 
the use of an assessment based tapering protocol would be clinically useful. Although 
symptoms of opioid and benzodiazepine withdrawal overlap, not all symptoms of 
benzodiazepine withdrawal are addressed by the WAT-1 such as insomnia and 
seizures.19 Based on our findings and the findings in similar studies, we agree that 
opioid tapering regimens should consider risk factors, such as opioid duration. Whether 
other factors, such as age, affect withdrawal is not completely clear. However it is clear 
that to successfully identify and manage opioid withdrawal symptoms, use of a valid tool 
is imperative.  Therefore, tolerance to the tapering regimen should be assessed daily 
using a validated pediatric assessment tool.  
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Table 1. Participant Characteristics (n=25) 
Variable Mean SDb Range 
Age (mo.)a             79.8            61.2             7 to 214 
 Median IQRc  Range 
LOMVd (days)                8.5       5     to   18.5 0 to 35 
ICU LOSe (days)               13      7.5   to   21.5 1 to 38 
 Count Percent  
Gender    
     Male 16 64%  
     Female 9 36%  
Race    
     Asian 1 4%  
     Black 12 48%  
     White 
 
11 44%  
     Other 
 
Ethnicity 
       
      Hispanic                                                            
       
      Non-Hispanic 
 
Admission Diagnosis 
 
1 
 
 
 
1
 
24 
4% 
 
 
 
4% 
 
96% 
 
      Trauma 
      
      Respiratory        
 
      Post-opf   
      
      Sepsis 
    
      Other           
 
                 4 
 
                 7    
 
                 5 
                  
                 3 
                  
                 6                     
            16% 
 
            28% 
 
            20% 
 
            12% 
 
          24% 
 
amo. = months;  bSD = Standard Deviation; c IQR- interquartile range; dLOMV= Length of 
Mechanical Ventilation; eICU LOS = Intensive Care Unit Length of Stay; fPost-op= Postoperative 
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Table 2.  WAT-1 Individual Variable Scores and Total Daily WAT-1 Score (Means and Standard Deviations) a 
Symptoms Day 1 
(N=25) 
Mean (SD) 
Day 2 
(N=25) 
Mean (SD) 
Day 3 
(N=24) 
Mean (SD) 
Day 4 
(N=21) 
Mean (SD) 
Day 5 
(N=21) 
Mean (SD) 
Day 6 
(N=21) 
Mean (SD) 
Day 7 
(N=18) 
Mean (SD) 
Loose watery stools 0. 38 (0.49) 0.36 (0.49) 0.33 (0.48) 0.33 (0.48) 0.43 (0.51) 0.29 (0.46) 0.33 (0.49) 
Vomiting/retching/ gagging  0.2 (0.41) 0.24 (0.44)  0.29 (0.46) 0.29 (0.46) 0.1 (0.3) 0.05 (0.22) 0.17 (0.38) 
Temperature >37.8oC  0.24 (0.44) 0.36 (0.49)  0.25 (0.44)  0.19 (0.4)   0.24 (0.44)   0.14 (0.36) 0.17 (0.38)  
State 0.16 (0.37) 0.08 (0.28) 0.13 (0.34)  0.14 (0.36) 0.14 (0.36) 0 (0) 0.06 (0.24) 
Tremor 0.12 (0.33) 0.12 (0.33) 0.21 (0.42) 0.05 (0.22) 0.05 (0.22)  0.05 (0.22) 0.06 (0.24) 
Sweating 0.12 (0.33) 0.32 (0.48) 0.25 (0.44) 0.43 (0.51) 0.29 (0.46) 0.19 (0.4) 0.22 (0.43) 
Uncoordinated/  
 repetitive movement 
0.08 (0.28) 0.12 (0.33) 0 (0) 0.05 (0.22) 0.1 (0.3) 0.1 (0.3) 0.11 (0.32) 
Yawning or sneezing  0.08 (0.28) 0.04 (0.2) 0.13 (0.34)  0.05 (0.22)  0.05 (0.22) 0.05 (0.22) 0.06 (0.24) 
Startle to touch 0.2 (0.41) 0.12 (0.33) 0.08 (0.28) 0.19 (0.4) 0.14 (0.36) 0.1 (0.3) 0.06 (0.24) 
Muscle tone 0.52 (1.8) 0.12 (0.33) 0.13 (0.34) 0.05 (0.22) 0.14 (0.36) 0.1 (0.3) 0.11 (0.32) 
Time to gain calm state 0.08 (0.28) 0.08 (0.28) 0.08 (0.28) 0 (0) 0.05 (0.22)  0.1 (0.44) 0 (0) 
 
Total WAT-1 score 
Mean (SD) 
 
1.8 (1.47) 
 
2 (1.68)  
 
1.96 (1.58) 
 
1.7 (1.45) 
 
1.76 (1.64) 
 
1.14 (1.28) 
 
1.28 (1.02) 
a WAT-1 = Withdrawal Assessment Tool-1. All items scored 0-1 except for time to gain calm - 0-2 points. Total WAT-1 score is the 
sum of all items (0-12). 
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Table 3. Opioid Exposure  
Variable Median IQRa Range 
Opioid Duration (days) 8.0 5.0 – 15.5 5.0 – 22.0 
Cumulative Opioid Dose (MEK)b 49.1 16.6 – 124.6 3.8 – 364.3 
Peak Opioid Dose (MEK) 9.8 3.0 – 16.8 0.7 – 34.6 
 aIQR= Interquartile Range 
 bMEK= Morphine Equivalents per Kilogram 
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Table 4. Opioid Taper (n=25)  
Opioid Change Na Median (MEK)b IQRc (MEK) Range (MEK) 
Day 1 to 2 25 -0.5 -3.20 – -0.05 -24.4 – 14.1 
Day 2 to 3 24 -0.24 -0.73 – 0.07 -16.2 – 1.6 
Day 3 to 4 24 -0.07 -0.64 – 0.15 -2.6 – 1.1 
Day 4 to 5 24 0.0 -0.34 – 0.54 -3.6 – 2.5 
Day 5 to 6 22 0.0 -0.73 – 0.06 -3.8 – 2.9 
Day 6 to 7 22 -0.23     -0.94 – 0.0 -3.7 – 2.0 
aN= Sample Size 
bMEK= Morphine Equivalents per Kilogram 
cIQR= Interquartile Range 
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Table 5. Multivariate Correlations (n=25) 
 Age 
(months) 
log 
Opioid 
Duration 
Peak Opioid 
Dose 
(MEK)a 
log 
Cumulative 
Opioid Dose 
(MEK) 
Mean Opioid 
Taper Rate 
Mean 
WAT-1b 
Day 1 to 7 
Max 
(WAT-1) 
Age 
(months) 
         1.00              -0.13          -0.41*       -0.40*         0.14        -0.22       -0.06 
log Opioid 
Duration 
         1.00           0.64*** 0.67***            0.23         0.33        0.38  
Peak Opioid 
Dose (MEK) 
      1.00 0.83***       -0.21         0.28        0.17 
log 
Cumulative 
Opioid Dose 
         1.00      -0.06         0.22        0.29 
Mean Opioid 
Taper Rate 
          1.00          0.05       0.21 
Mean WAT-1  
Day 1 to 7 
              1.00 0.83*** 
Max(WAT-1)       1.00 
a MEK = Morphine Equivalents per Kilogram 
b WAT-1 = Withdrawal Assessment Tool 
*p < 0.05 
**p < 0.01   
***p < 0.001 
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Figure 1. WAT-1 (need to add post converting document to pdf) 
Copyright permission obtained from Franck 
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                 Figure 2. Mean Opioid Dose and WAT-1 Score over Time (n=25)  
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I. TITLE    
 
Opioid withdrawal signs and symptoms  in the pediatric patient during opioid tapering 
 
 
II. STAFFING 
A.  In the table below (add additional rows as needed), indicate: (1) key project personnel including the principal 
investigator and individuals from other institutions, (2) their qualifications, and (3) a brief description of their 
responsibilities. 
 
NAME OF INDIVIDUAL QUALIFICATIONS RESPONSIBILITIES 
Mary Jo Grap PhD, RN, FAAN, 
ACNP 
• VCU School of Nursing, Adult 
Health and Nursing Systems, 
Professor  
• Panel Expert in Pain Management, for 
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Care Nurses  
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B.  Describe the process that you will use to ensure that all persons assisting with the research are adequately 
informed about the protocol and their research-related duties and functions. 
 
 Prior to beginning the study, all team members will meet to establish agreement on process, duties and function. 
Recruitment, enrollment, data collection, data management and analysis, final report and dissemination of findings will be 
performed by Ms. Fisher.  Dr. Ameringer and Dr. Younger will provide pediatric nursing consultation, pediatric pain 
consultation as well as consultation on statistical analysis and quantitative methods. Dr. Elswick will provide expert 
consultation for the statistical analysis portion of the study. All team members will be appraised through monthly reports 
via email during data collection. All team members will meet prior to data analysis and prior to final report. 
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III. CONFLICT OF INTEREST 
Describe how the principal investigator and sub/co-investigators might benefit from the subject’s participation in this 
project or completion of the project in general. Do not describe (1) academic recognition such as publications or (2) 
grant or contract based support of VCU salary commensurate with the professional effort required for the conduct of 
the project 
 
Dr. Grap – no conflicts to declare 
Dr. Ameringer- no conflicts to declare 
Dr.Younger – no conflicts to declare 
Dr. Elswick – no conflicts to declare 
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IV. RESOURCES 
Briefly describe the resources committed to this project including: (1) time available to conduct and complete the 
research, (2) facilities where you will conduct the research, (3 availability of medical or psychological resources that 
participants might require as a consequence of the research (if applicable), and (4) financial support. 
 
1. Ms. Fisher will devote 6 hours per week towards conduct of this study; data collection is anticipated to take 
approximately 4 - 6 months. 
2. Study setting is VCU Medical Center, Main 7 PICU and acute care pediatric units 
3. No anticipated need for psychological resources; all participants will be under the care of a medical team 
4. There is no financial support for this study 
 
 
V. HYPOTHESIS 
Briefly state the problem, background, importance of the research, and goals of the proposed project. 
 
 Routine use of sedation and analgesia for ventilated children in the intensive care unit is essential for the comfort 
and safety of the child to protect the child from self-harm such as unplanned endotracheal extubation, anxiety related 
increased oxygen demand and ventilator dysynchrony.1 However the therapeutic goal of providing adequate analgesia and 
sedation often results in days to weeks of continuous exposure to opioids and sedatives. Continuous exposure may result in 
iatrogenic opioid and sedative dependence. Few data have been published on the incidence of opioid withdrawal in the 
pediatric patient. The studies that have been published vary widely on incidence of opioid withdrawal (0-100%).2-5  Studies 
of opioid withdrawal conducted in the pediatric population have used neonatal withdrawal tools2-7 or no opioid assessment 
tool was used.3,4,8,9 The use of developmentally inappropriate instruments such as neonatal opioid withdrawal instruments 
may result in conclusions that are flawed. In 2008, Franck et al. developed the Withdrawal Assessment Tool-1 (WAT-1), a 
pediatric opioid withdrawal scale.9,10 At this time, the WAT-1 is the only validated pediatric opioid withdrawal assessment 
tool.  In 2009, Ista et al. developed a promising opioid and benzodiazepine withdrawal tool, the Sophia Observation 
withdrawal Symptoms scale (SOS), but psychometric properties have yet to be published.11 Except for the initial 
instrument validation studies of the WAT-1, no studies have been conducted to identify the incidence of pediatric opioid 
withdrawal using a validated pediatric opioid withdrawal assessment tool. In addition there is little data about factors that 
may affect the frequency of withdrawal signs and symptoms including opioid exposure (cumulative opioid dose, peak 
opioid dose, duration of opioid exposure), opioid taper rate, severity of illness and the child’s age. Therefore, the purpose 
of this study is to describe the frequency of opioid withdrawal signs and symptoms and to identify factors associated with 
these opioid withdrawal signs and symptoms.  
 
  
VI. SPECIFIC AIMS   
 
The specific aims of this study are to: 
1. describe the signs and symptoms (WAT-1) of opioid withdrawal in children undergoing opioid tapering 
2. examine the relationship among opioid withdrawal signs and symptoms (WAT-1), opioid exposure (cumulative opioid 
dose, peak opioid dose, duration of opioid exposure), opioid taper rate, severity of illness and the child’s age.  
 
 
  
VII. BACKGROUND AND SIGNIFICANCE 
Include information regarding pre-clinical and early human studies.  Attach appropriate citations. 
Rev. Date: 1-31-2010                                                    IRB USE - Do Not Delete 
3                                                                                                                                               [Version # 2 or 4-4-11  
 
 Over 90% of critically ill children receive opioids.12 Opioids are used routinely in the pediatric intensive care 
population for analgesia, sedation, blunting of physiologic responses to stress, and safety.2,12,13 In addition, the synergistic 
effect of opioids in combination with benzodiazepines allows for dose reductions of both opioids and benzodiazepines.14 
Continued exposure to opioids can lead to opioid dependence or tolerance. Opioid dependence is defined as a state of 
adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid 
dose reduction, decreasing blood level of the drug, and/or administration of an antagonist.15 Opioid tolerance is defined as 
a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug's 
effects over time.15 In children, physical dependence may occur in as little as two to three days of continuous opioid 
therapy.16  Opioid dependence has been shown to develop even more rapidly in neonates and infants than in older children 
or adults.17 Once the child no longer needs the opioid or sedative, the medications are reduced over time. Since tapering 
routines vary among practitioners, it is not uncommon for nurses to witness signs and symptoms of opioid withdrawal in 
this vulnerable population.18  Opioid withdrawal signs and symptoms in adults include hiccups, goose bumps, chills, fever, 
tachycardia, tachypnea, hypertension, agitation, restlessness, insomnia, nausea, vomiting, diarrhea, cramps, lacrimation, 
rinorrhea, yawning, diaphoresis, mydriasis, bone pain, muscle aches and spasms, and seizures.16 Opioid withdrawal signs 
and symptoms in children include diarrhea, nausea, vomiting, fever, sweating, mottling, tremor, agitation, frequent 
yawning, frequent sneezing, motor disturbance, insomnia and hypertonia.2-6,8-11,13,18-23 Data concerning factors that affect 
opioid withdrawal signs and symptoms are limited. Although no studies investigating the effect of gender on withdrawal 
signs and symptoms have been conducted in humans, there is evidence of gender differences in opioid tolerance and 
incidence of withdrawal in rats. In a study conducted by Craft et al., male rats were found to have a higher withdrawal 
score than female rats.24 In addition, there is limited data that show length of stay (LOS) in the PICU, duration of 
mechanical ventilation (VLOS) and cumulative opioid dosage (mg/kg) are positively associated with signs and symptoms 
of opioid withdrawal. 5,13,23 Acute effects of withdrawal signs and symptoms are numerous and can be dangerous. Diarrhea 
and vomiting can lead to dehydration. Tachycardia may lead to unnecessary intravenous fluid resuscitation or even 
cardiology evaluations. Routine use of validated opioid withdrawal assessment tools or algorithms is rare.9 18 which may 
contribute to delays in diagnosis of opioid withdrawal syndrome and proper treatment. Potential long term effects of 
poorly managed withdrawal symptoms are unknown; however, possible consequences include prolonged tapering duration 
in response to attempts to alleviate withdrawal signs and symptoms as well as needless physical and emotional suffering. 
Of note, only one position statement on opioid withdrawal in children is available in the literature. The American 
Academy of Pediatrics (AAP) position statement on neonatal drug withdrawal recommends multimodal maternal screening 
for opioid use, enhanced recognition of signs of opioid withdrawal, routine use of appropriate opioid withdrawal tools, and 
medication recommendations for opioid or sedative withdrawal.25 However, no such statement exists for the pediatric 
population.    
 
 
 
VIII. PRELIMINARY PROGRESS/DATA REPORT 
If available. 
 
1. Survey of opioid tapering practices of pediatric healthcare providers: A national perspective.18 The purpose of this 
study was to describe the current opioid tapering practice of a national sample of health care providers consisting of nurse 
practitioners, physician assistants and physicians. Data were collected through a web based survey developed by the 
investigator. The 11 item survey was developed through careful review of the literature, evaluated by clinical experts in 
pediatric pain management and revised based on their feedback. The survey included multiple choice and open ended 
questions that evaluated the following: existence and use of guidelines for opioid tapering, personal preference for opioid 
tapering, use of expert consultation for opioid tapering, use of opioid withdrawal assessment tool, and pharmacological 
preference for management of signs and symptoms of opioid withdrawal. Content validity and clarity were then 
established by a panel of 6 pediatric providers with expertise in advanced practice nursing, medicine and survey methods.  
Pilot testing was conducted using 8 pediatric health care providers and further revisions made. The resulting survey was 
distributed to pediatric health care providers via international and national pediatric pain and palliative care email list 
serves. One hundred and four participants from pediatric pain and palliative care list serves responded to the survey. Of 
these, the majority were physicians (62%) followed by pediatric nurse practitioners (16%), clinical nurse specialists (15%), 
family nurse practitioners (5%), and doctors of osteopathy (2%). The majority of respondents were employed in an 
academic children’s medical center (52%). Median age of years in pediatric practice was 16.33 years. The majority (60%) 
did not have a written opioid tapering protocol in their practice setting. Respondents without a protocol described regimens 
for opioid withdrawal that varied greatly. Approximately half (n=54) of the 104 respondents used an opioid withdrawal 
assessment tool. Of those using an assessment tool, the majority used the WAT-113 (n=22), followed by the Finnegan 
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Neonatal Abstinence Score26 (n=14), Clinical Opiate Withdrawal Scale27 (n=6) and the Sophia Observation withdrawal 
Symptoms scale11 (n=3). This study provided data illustrating the wide variation in opioid tapering practices among 
practitioners. 
 
  
IX. RESEARCH METHOD AND DESIGN 
Include a brief description of the project design including the setting in which the research will be conducted and 
procedures.  If applicable, include a description of procedures being performed already for diagnostic or treatment 
purposes. 
 
 The specific aims of this prospective, descriptive study are to 1) describe the signs and symptoms (WAT-1) of 
opioid withdrawal in children undergoing opioid tapering and 2) examine the relationship among opioid withdrawal signs 
and symptoms (WAT-1), opioid exposure (cumulative opioid dose, peak opioid dose, duration of opioid exposure), opioid 
taper rate, severity of illness and the child’s age.  
 
Setting 
 The study will be conducted in the Pediatric Intensive Care Unit (PICU), the Pediatric Progressive Care Unit 
(PPCU) and the acute care pediatric units at the Children’s Hospital of Richmond, VCU Medical Center campus in 
Richmond, Virginia. The PICU, the PPCU and acute care areas, admit children with a wide range of pediatric diagnoses 
providing enhanced generalizability of study findings.  Dr. Grap, the student’s primary advisor, is an acute care nurse 
practitioner and researcher who has conducted numerous clinical studies in the adult intensive care units as well as one 
previous study in the PICU. Ms. Fisher, the student PI, is a pediatric nurse practitioner at the Children’s Hospital of 
Richmond and has conducted one prior study in the PICU. Dr. Ameringer is an assistant professor of pediatric nursing at 
the VCU School of Nursing. She has conducted several clinical studies in the VCUHS pediatric units. 
 
Table 1. Characteristics of study units from which participants will be enrolled (FY 2009) 
Unit / bed # Annual Admissions Average LOSa (in days) Average VLOSb (in days) 
PICU/  12 477 4.0 7.1 
PPCU/  7 348 3.2 NAc 
Acute Care Pediatrics 
M7E/  17 
M7C/  24 
1991 3.9 NAc 
a
 = Length of Stay 
b
 = Ventilator Length of Stay 
c 
= Not applicable 
Sample 
 The sample of up to 100 will be drawn from all patients, ages 2 weeks to 21 years admitted to the Children’s 
Hospital of Richmond Pediatric Intensive Care Unit (PICU) and who have received continuous infusion opioids for greater 
than 5 days.2,5,13,21  The WAT-1 was developed for the 2 week to 18 year range.12 Since the PICU and pediatric floors 
accept and treat patients up to 21 years of age, the age inclusion criteria will be adjusted to more adequately reflect the age 
population seen in the PICU, PPCU and pediatric acute care units. Numerous opioid withdrawal studies have found that 
opioid tolerance may occur after 5 days of opioid exposure.5,17,22 Previous studies have found that opioid withdrawal signs 
and symptoms are highest during taper days 1-6, therefore  data collection will occur daily for up to 7 days.3,6,8,10,28 In order 
to increase external validity, we will include all admitting diagnoses. Pediatric patients (2 weeks to 21 years) from all 
ethnic and racial backgrounds will be recruited.  Since one of the variables of the WAT-1 is restlessness, children with 
paralysis of one or more limbs or who are receiving neuroparalytics will be excluded.  Should the enrolled participant be 
transferred to another pediatric unit (PPCU, M7C or M7E) during the up to 7 days of data collection, the student PI will 
continue data collection on those units.  Based upon the sample size and the student PIs ability to collect data on up to 4 
patients per day, a data collection period of 6 months is feasible.  
 
Methods  
Measurement of major variables 
 
1. Opioid withdrawal signs and symptoms 
 Known opioid withdrawal signs and symptoms in the pediatric population include gastrointestinal (diarrhea, 
nausea, vomiting), autonomic (fever, sweating, mottling) and central nervous systems (tremor, agitation, frequent yawning, 
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frequent sneezing, motor disturbance, hypertonia).2-6,8-11,13,18-23 Opioid withdrawal signs and symptoms will be measured 
using the 11 item Withdrawal Assessment Tool – 1(WAT-1). The WAT-1 is an 11 item pediatric opioid withdrawal 
instrument that includes measures of gastrointestinal (diarrhea, nausea, vomiting), autonomic ( fever, sweating) and central 
nervous system (tremor, sedation state, uncoordinated movement, yawning or sneezing, startle to touch, muscle tone and 
time to gain calm) measures of opioid withdrawal.13 This pediatric instrument is the revised version of the original 21 item 
Opioid Benzodiazepine Withdrawal Scale (OBWS).10 The original instrument was tested in a pediatric critical care 
population (n=15 patients; 693 observations) ranging in age from 6 weeks to 28 months. The result of the original testing 
of the proposed 21 item OBWS (sensitivity = 50%; reliability = 87%) led to a revision of the OBWS to the 19 item WAT-
1. The 19 item WAT-1 was tested in a pediatric critical care population (n=83; 1040 observations) ranging in age from 6 
months to 10 years. Redundant signs and symptoms and symptoms with low levels of association with withdrawal 
intensity ratings were eliminated resulting in the current recommended 11 item tool.13 The WAT-1 (Appendix A) showed 
superior psychometric properties (sensitivity = 87%; specificity = 88%) compared to the initial testing of the OBWS 
(sensitivity = 50%; specificity= 80%; IRR=0.8). Although inclusion criteria for the validation of the WAT-1 ranged from 2 
weeks to 18 years, the actual sample ranged from age 6 months to 10 years. Since the WAT-1 is validated only for the 6 
month to 10 year age group, children aged <6 months or >10 years will be excluded. The WAT-1 includes the State 
Behavioral Scale (SBS) which was originally validated for assessment of pre and post stimulus state (Appendix B).1 The 
SBS was designed to evaluate the young patient’s response to a progressive stimulus. Negative numbers reflect levels of 
sedation. Positive numbers reflect levels of agitation. A score of zero reflects neither agitation nor sedation. “The 
progressive stimulus used in the SBS assessment provides a standard stimulus for observing signs of withdrawal.” 1 Since 
the SBS is a subscale of the WAT-1 score, it will be completed along with each WAT-1 measurement. 
  
2. Opioid exposure  
 Opioids are used routinely in the pediatric intensive care population in order to reduce pain, anxiety and morbidity. 
Continuous infusion of both an opioid (fentanyl) for analgesia and a benzodiazepine (midazolam) for sedation is routine 
practice in the PICU for all mechanically ventilated infants and children. Given the synergistic effects of benzodiazepines 
and opioids, the addition of an opioid has been associated with up to 50% dose reductions of midazolam.29 Fentanyl is 
preferred to morphine since it releases less histamine, thus decreasing the associated hypotension.19 Numerous clinical 
studies have found that the duration of opioid receptor occupancy is related to the development of opioid tolerance.7,10,30,31 
In a prospective study conducted by Katz et al (1994), 23 infants (<23 months) were observed for signs of opioid 
withdrawal post opioid exposure.5 They found a positive correlation of dosage (p<0.005) and length of exposure (p 
<0.0001) on occurrence of opioid withdrawal. In fact, a dose of 2.5mg/kg fentanyl or more than 9 days exposure was 
100% predictive of withdrawal. Since withdrawal signs and symptoms may be affected by both opioid dose (cumulative 
and peak) as well as duration, in this study opioid exposure will consist of all of these factors.  
 
 Opioid Dose (Cumulative and Peak). In a prospective study of infants ranging in age from 1 week to 22 months ,  
Katz, Kelly & His found that a total dose of 1.5mg/kg was associated with a 50% rate of opioid withdrawal.5 Other studies 
conducted in children have found a similar dose dependent relationship.4,6,17  In a prospective, multiple case study (n=27), 
Ducharme and colleagues examined the effects of variable opioid taper rates on occurrence of opioid withdrawal on PICU 
patients (age 0-19 years), there was a minimal correlation between opioid peak dose and occurrence of withdrawal (r = 
0.34; p <0.05).4 In a prospective, descriptive opioid withdrawal study of critically ill children ( < 25 months), French and 
Nocera found a significant correlation between cumulative fentanyl dose and opioid withdrawal score (r = 0.76; p<0.01).6  
In a retrospective study of neonates, Arnold and colleagues found a total dose of 1.6mg/kg to be associated with the 
development of opioid withdrawal.17 There was no significant difference in peak opioid dose between the neonates who 
had opioid withdrawal and those infants with no signs or symptoms of opioid withdrawal. Because the literature shows 
some relationship between cumulative and peak opioid dose on occurrence of opioid withdrawal, opioid dose will be 
described as both cumulative and peak.  Peak dose will be determined by calculation of daily opioid dose.  To compare 
analgesics across types, all opioids can be converted to a common drug (i.e. morphine) and reported as morphine 
equivalents per kilogram (MEK). 8,21 For this study, fentanyl conversion to morphine will be calculated by the formula 
10mg of IV morphine = 0.1mg IV fentanyl.32 Morphine equivalents will be divided by the patient’s body weight to 
determine MEK. Peak and cumulative MEK will be calculated pretaper and daily at 10am during taper. All opioids will be 
converted to morphine equivalents per kilogram (MEK). Daily dose of MEK will be calculated. The largest daily MEK 
will be recorded as the peak opioid dose. Cumulative dose will be determined by summation of daily MEKs prior to 
initiation of opioid taper.  
 
 Opioid Duration. Previous studies in children have found a correlation between opioid duration prior to taper with 
occurrence of opioid withdrawal signs and symptoms.4-6,21 Ducharme and colleagues found a moderate association 
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between opioid duration and occurrence of opioid withdrawal (r = 0.41; p<0.01).4 Katz, Kelly & Hsi found that a duration 
of 5 days or more of fentanyl exposure was 50% predictive of opioid withdrawal.5 French and Nocera found a significant 
correlation between duration of fentanyl exposure and opioid withdrawal score (r = 0.70; p<0.05).6  In a prospective, 
repeated measures design study of critically ill children (n= 79; ages 0 to 16 years), Ista and colleagues found a significant 
correlation between duration of opioid exposure and severity of opioid withdrawal (r= 0.52; p<0.001).21Opioid duration 
will be calculated as the number of days of continuous or scheduled opioid exposure prior to initiating opioid taper. 
Children with at least 5 days of opioid exposure will be eligible for the study. 
 
3. Opioid taper rate  
 The goal of tapering opioids is to safely wean the opioid from the patient while avoiding the incidence of opioid 
withdrawal. There is little empirical evidence to guide the practice of opioid tapering.4,8-10 Although some 
recommendations exist in the literature, few recommended guidelines have been tested in the pediatric 
population.2,4,7,8,10,30,31 Berens et al. (2006) conducted  a double-blinded, randomized control trial using methadone and 
found a 20% incidence of need for rescue medications to treat signs and symptoms of opioid withdrawal.2 Of those that 
have been tested, no guideline was associated with a 0% incidence of opioid withdrawal signs and symptoms.4,7-10,30  
 A recent survey of international pediatric pain management providers conducted by Fisher found a wide variation 
in opioid tapering practice (see preliminary study #1). Opioid tapering practices were divided into two categories: 
conservative or aggressive. 69 % of practitioners in the study used a conservative method, defined as tapering reduction of 
20% or less per day. 12 % used a more aggressive method, greater than 20% dose reduction per day. Within each category, 
tapering practices varied. Reported conservative regimens ranged from 10% reductions per week to 10% every day. 
Aggressive regimens varied from 30% every 2 days to 50% per day. Since rates of taper vary depending on clinician, 
opioid tapering rate will be defined as percentage change in total opioid dose per day, expressed in morphine equivalent 
units per kilogram (MEK) of the child’s body weight. Nonscheduled opioids that are administered will also be included in 
the daily opioid tapering rate calculation. In addition, medications that may alleviate withdrawal signs and symptoms such 
as benzodiazepines, α-adrenergic (clonidine, dexmedetomedine), antiemetics and antipyretics will be recorded. Although 
several studies recommended opioid dose reductions ranging from 10-20% per day, none of the studies resulted in an 
absence of opioid withdrawal signs and symptoms.2,4,7,10,30,31  At this point in time, there is no gold standard for opioid 
tapering in children. 
 
 4. Severity of Illness Severity of illness is used to further describe the population and has been included in previous 
pediatric opioid withdrawal studies.2,13,21 In a prospective, randomized trial comparing the effect of a 5 day methadone 
taper versus a 10 day methadone taper on incidence and severity of opioid withdrawal, the investigators no difference in 
severity of illness in either group. In the prospective psychometric evaluation of the WAT-1, severity of illness was 
included only as a demographic characteristic.13  Similarly, Ista and colleagues included severity of illness only as a 
demographic characteristic.21 Given the pervasive nature of opioid withdrawal signs and symptoms on multiple systems 
including the central nervous system, autonomic nervous system and gastrointestinal system, a potential relationship 
between severity of illness and opioid withdrawal signs and symptoms is possible. In addition, severity of illness may 
impact the individual child’s need for analgesics and sedatives. To our knowledge, this study would be the first to examine 
the relationship between severity of illness and frequency of signs and symptoms of opioid withdrawal. The revised 
Pediatric Index of Mortality (PIM2) will be used to measure severity of illness.33 The PIM-2 (Appendix C) has been used 
to measure severity of illness in cardiac surgery patients, 34 severe head injury,35 medical surgical,36 and multidisciplinary 
PICU populations.37 The PIM2 will be measured, based on data from the previous 24 hours,  at time of study enrollment.  
 
5. Age.  Few studies have evaluated the effect of age on opioid withdrawal signs and symptoms.5,13 Katz and colleagues 
found no correlation between age and incidence of opioid withdrawal.5 Franck found some age related differences in 
incidence of specific opioid withdrawal signs and symptoms.13 For example, there was a higher incidence of vomiting in 
the 0-2 year age group (12.3%) compared to the >6 years age group (3.2%). Age, in months, will be measured at the time 
of study enrollment.  
 
6. Additional Demographics 
 Other demographic data (race, gender, hospital admission diagnosis, length of mechanical ventilation, ICU length 
of stay) will be collected to describe the sample.  
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Table 2:Key study variables and their measurement 
Variable Measure Measurement Interval 
Opioid withdrawal signs and 
symptoms 
WAT-1 (0-12) Daily at same time  for 7 days 
Opioid exposure 
 Opioid dose 
 
  
 Opioid duration 
 
Peak opioid dose (in MEK)  
Cumulative opioid dose ( in MEK) 
 
Number of days of opioid exposure 
 
Once at time of study enrollment 
Once at time of study enrollment  
 
Once at time of study enrollment 
Opioid taper rate 
 
 opioid mg/kg per day (MEK per day) Daily for 7 days 
Severity of Illness Pediatric Index of Mortality (PIM2) Once at time of study enrollment 
Age Age in months Once at time of study enrollment 
Additional demographic data Race, gender, admission diagnosis, 
weight in kilograms, length of 
mechanical ventilation (days), ICU 
length of stay (days) 
Once at time of study enrollment – 
ICU LOS may not be available at time 
of enrollment  
Note. WAT-1 = Withdrawal Assessment Tool -1. MEK = Morphine equivalents per kilogram 
 
Procedure: 
 Prior to beginning the study, the student PI will provide an informational inservice to the pediatric nursing 
leadership and staff of the involved units (PICU, PPCU, M7C & M7E). The student will identify patients who meet 
selection criteria through daily rounds on the PICU. Since this is a descriptive study, there will be no change in the medical 
plan of the participants. No more than minimal risk is anticipated. Data obtained will not affect the participant’s routine 
care nor will it be used in the clinical management of opioid tapering. Waiver of assent is being requested since the 
intended participants will be sedated during the observation period. Permission will be obtained from the parent/legal 
guardian at time of study enrollment. 
 Should the child awaken during the data collection time period, the student investigator will debrief them on the 
study. Data collection timing will occur each afternoon between 10 AM and 4 PM during times of routine care in order to 
allow a consistent time point from the previous day’s opioid dosing changes and avoid the usually busy early morning 
clinical rounds. The exact time will be negotiated with the bedside nurse in order to minimize any potential disruption of 
routine care. Data collection will occur daily for up to 7 days.  Decisions about individual opioid therapy for these subjects 
including opioid duration and dosage will be made by the medical team. 
 At the time of study enrollment, the student PI will collect the following data from the electronic medical record 
(EMR) and bedside flowsheet:  medications received within the past 24 hours, data to calculate opioid cumulative dose (in 
MEK) peak opioid dose (in MEK),  and number of days of opioid exposure prior to study enrollment demographic data 
(age, race, gender, admission diagnosis, PIM2, weight in kilograms) 
 Data collection for the opioid taper rate will occur each day for up to 7 days. The student PI will collect opioid 
dose information given over the past 24 hours (8a to 8a). All opioids will be converted to MEK. The sum of the MEKs will 
be recorded as the MEK/day. The MEK/day will be compared to the previous day’s MEK/day and the percentage 
reductions per day will be calculated. 
 Data collection for the WAT-1 will begin with a review of the EMR and flowsheet for the previous 12 hours, as 
per the WAT-1 instructions. The student PI will then record incidence of any symptom listed on the WAT-1 including 
temperature >37.8 C, vomiting/wretching/gagging and loose/watery stools. Next, the student will observe the participant 
undisturbed for 2 minutes, during which time data will be collected on several variables of the WAT-1 scale: state (SBS), 
tremor, sweating, uncoordinated/repetitive movements and yawning or sneezing. Next, the student PI will observe the 
patient during a progressive stimulus. The progressive stimulus will entail first calling the participant’s name in a calm 
voice. If the participant does not respond, then the student PI will call the participant’s name and gently touch the arm or 
leg. If the participant does not respond, the student PI will observe the patient during a planned noxious procedure such as 
endotracheal suctioning or turning, which will be performed by the bedside nurse. During the 1 minute stimulus 
observation, the student PI will collect data on muscle tone and startle to touch. The WAT-1will be measured similarly 
daily for up to 7 days. 
 Should a participant transfer to the progressive (PPCU) or acute care pediatric (M7C & M7E) units, the student PI 
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will continue to collect data on the new unit until either completion of 7 days of data collection or hospital discharge. 
 
 
 
X.  PLAN FOR CONTROL OF INVESTIGATIONAL DRUGS,  BIOLOGICS, AND DEVICES.  
For investigational drugs and biologics:  IF IDS is not being used, attach the IDS confirmation of receipt of the 
management plan..  See item #11 on Initial Review form. 
For investigational and humanitarian use devices (HUDs): Describe your plans for the control of investigational 
devices and HUDs including: (1) how you will maintain records of the product’s delivery to the trial site, the inventory 
at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s); (2) 
plan for storing the investigational product(s)/ HUD as specified by the sponsor (if any) and in accordance with 
applicable regulatory requirements; (3) plan for ensuring that the investigational product(s)/HUDs are used only in 
accordance with the approved protocol; and (4) how you will ensure that each subject understands the correct use of 
the investigational product(s)/HUDs (if applicable) and check that each subject is following the instructions properly 
(on an ongoing basis). 
 
NA 
 
 
XI. DATA ANALYSIS PLAN 
For investigator–initiated studies. 
 
             Demographic variables will be descriptively summarized. Measures of central tendency (mean, median) and 
dispersion (standard deviation, range) on continuous data, and frequency and count on categorical data will be computed as 
appropriate. 
 The first aim of the study (specific aim #1) is to describe the signs and symptoms of opioid withdrawal (WAT-1) 
in children undergoing opioid tapering.  Descriptive statistics (means and standard deviations) will be used. 
 The second aim (specific aim #2) is to examine the relationship among the maximum opioid withdrawal signs and 
symptoms (WAT-1), opioid exposure (cumulative opioid dose, peak opioid dose, duration of opioid exposure) summed to 
day of maximum amount, opioid taper rate (range of percentage changes), severity of illness (PIM2) and the child’s age. In 
order to account for variance of opioid choice amongst practitioners, all opioids will be converted to morphine equivalents.   
Distributions of all study variables will be examined to determine the need for transformations. Multiple regression will be 
performed to evaluate the relationship among opioid withdrawal signs and symptoms (WAT-1), and opioid tapering rate 
(range of percentage changes), opioid exposure (cumulative opioid dose, peak opioid dose, duration of opioid exposure), 
and the child’s age. 
 
 
 
  
XII. DATA AND SAFETY MONITORING 
• If the research involves greater than minimal risk and there is no provision made for data and safety monitoring 
by any sponsor, include a data and safety-monitoring plan that is suitable for the level of risk to be faced by 
subjects and the nature of the research involved.   
• If the research involves greater than minimal risk, and there is a provision made for data and safety monitoring 
by any sponsor, describe the sponsor’s plan. 
• If you are serving as a Sponsor-Investigator, identify the Contract Research Organization (CRO) that you will be 
using and describe the provisions made for data and safety monitoring by the CRO.  Guidance on additional 
requirements for Sponsor-Investigators is available at http://www.research.vcu.edu/irb/wpp/flash/X-2.htm 
 
The research involves no more than minimal risk. Since this is an observational study, there will be no change in the 
medical plan of the participants. Data obtained will not affect the participant’s routine care nor will it be used in the 
clinical management of opioid tapering.  Data will be entered into an electronic record. Access to this password protected 
site will be limited to the student investigator. Data will be shared only with the investigators listed on this research plan 
during monthly study meetings. 
 
 
  
XIII. MULTI-CENTER STUDIES 
If VCU is the lead site in a multi-center project or the VCU PI is the lead investigator in a multi-center project, 
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describe the plan for management of information that may be relevant to the protection of subjects, such as reporting 
of unexpected problems, project modifications, and interim results. 
 
 
NA 
 
XIV. INVOLVEMENT OF NON-VCU INSTITUTIONS/SITES (DOMESTIC AND FOREIGN)   
1. Provide the following information for each non-VCU institution/site (domestic and foreign) that has agreed to 
participate: 
• Name of institution/site 
• Contact information for institution/site 
 
NA 
 
 
2.   For each institution, indicate whether or not it is “engaged” in the research (see OHRP’s guidance on 
“Engagement of  
Institutions in Research” at http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html.)  
 
NA 
 
3.   Provide a description of each institution’s role (whether engaged or not) in the human subjects research, adequacy 
of the facility (in order to ensure human subject safety in the case of an unanticipated emergency), responsibilities of 
its agents/employees, and oversight that you will be providing in order to ensure adequate and ongoing protection of 
the human subjects.  You should only identify institutions that have agreed to participate.  If additional institutions 
agree to participate at a later time, they must be added by amendment to the protocol.   
 
 
NA 
 
4.   For each institution that is “engaged” provide an OHRP Federalwide Assurance (FWA) # if: (1) the research is not 
exempt, AND (2) the research involves a DIRECT FEDERAL award made to VCU (or application for such).  
 
NOTE: Additional guidance at http://www.research.vcu.edu/irb/wpp/flash/XVII-6.htm, and 
http://www.research.vcu.edu/irb/wpp/flash/XVII-11.htm. 
 
 
NA 
 
  
XV. INVOLVEMENT OF INDEPENDENT INVESTIGATORS 
 
INDEPENDENT INVESTIGATOR:  an individual who is acting independently and not acting as an agent or employee of 
any institution or facility while carrying out his or her duties in the research protocol. Additional guidance at 
http://www.research.vcu.edu/irb/wpp/flash/XVII-15.htm. 
 
ENGAGEMENT IN RESEARCH:  An independent investigator becomes "engaged" in human subjects research when 
he/she (i) intervenes or interacts with living individuals for research purposes; or (ii) obtains individually identifiable 
private information for research purposes [45 CFR 46.102(d)-(f)]. See OHRP’s guidance on “Engagement of 
Institutions in Research” at http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html. 
 
1.  Provide a list of independent investigators.  
 
 
2.  For each independent investigator indicate whether or not he/she is “engaged” or “not engaged” in the research  
  
3.  For each independent investigator who is “engaged”: (1) describe his/her role with human subjects/identifiable 
Rev. Date: 1-31-2010                                                    IRB USE - Do Not Delete 
10                                                                                                                                               [Version # 2 or 4-4-11  
human data, AND (2) describe YOUR oversight of his/her involvement.   
 
NA 
 
 
NOTE: If an independent investigator is “engaged,” and the research is (1) not exempt AND (2) involves a DIRECT FEDERAL 
award made to VCU (or application for such), the independent investigator must sign a formal written agreement with VCU 
certifying terms for the protection of human subjects. For an agreement to be approved: (1) the PI must directly supervise all 
of the research activities, (2) agreement must follow the ORSP template, (3) IRB must agree to the involvement of the 
independent investigator, AND (4) agreement must be in effect prior to final IRB approval.  
 
XVI. HUMAN SUBJECTS INSTRUCTIONS (Be sure to use the sub-headings under A-I) – you will need to update all this 
when ALL the previous sections are finalized .. I am not going to review this until all that is OK …  
ALL sections of the Human Subjects Instructions must be completed with the exception of the section entitled 
“Special Consent Provisions.”  Complete that section if applicable. 
 
 
A.  DESCRIPTION 
Provide a detailed description of the proposed involvement of human subjects or their private identifiable data in the 
work.  
 
 
Data will be obtained from the electronic medical record and direct observation of the participant. Data will include: opioid 
withdrawal score (WAT-1),  opioid taper rate (total dose of opioid per day in MEK), medications, pretaper peak MEK, 
pretaper cumulative MEK, number of days of exposure to opioids prior to taper, age of participant, gender, race, diagnosis, 
weight (for use in calculation of MEK). 
The participants in this study will be observed only in this descriptive study. The observation period of 7 minutes for data 
collection is anticipated to be minimally intrusive and should not affect clinical care since the timing of daily data 
collection will be negotiated with the bedside nurse to be conducted during times of routine nursing care. 
 
 
 
B.  SUBJECT POPULATION 
Describe the subject population in terms of sex, race, ethnicity, age, etc., and your access to the population that will 
allow recruitment of the necessary number of participants.  Identify the criteria for inclusion or exclusion of any 
subpopulation and include a justification for any exclusion.  Explain the rationale for the involvement of special cases 
of subjects, such as children, pregnant women, human fetuses, neonates, prisoners or others who are likely to be 
vulnerable.  If you plan to allow for the enrollment of Wards of the State (or any other agency, institution, or entity), 
you must specifically request their inclusion and follow guidance on Wards and Emancipated Minors in the VCU IRB 
Written Policies and Procedures (specifically WPP#: XV-3) available at 
http://www.research.vcu.edu/irb/wpp/flash/XV-3.htm.  
 
Participant recruitment will occur at the Children’s Hospital of Richmond, VCU Health System campus. The 7th floor 
Pediatric floor will be the site of all participant recruitment. All pediatric patients (ages 2 weeks to 21 years) who have 
received continuous infusion opioids for >5 days will be included in recruitment efforts.  Patients will not be excluded for 
race, sex, or ethnicity. Access to the population will be facilitated by the student PI who is a Pediatric Nurse Practitioner 
employed by the Children’s Hospital of Richmond. Participants will be recruited over a 6 month data collection period. 
 
 
C.  RESEARCH MATERIAL 
Identify the sources of research material obtained from individually identifiable living human subjects in the form of 
specimens, records, or data.  Indicate whether the material or data will be obtained specifically for research purposes 
or whether use will be made of existing specimens, records, or data. 
 
Data will be obtained from the Electronic Medical Record (EMR), bedside flowsheet and observation. Once the data has 
been entered on computer, only code numbers will be associated with all forms and materials. Only the investigators will 
have access to the data. Once the participant is enrolled in the study, demographic data will be collected from the EMR. 
Existing data (see list below) that is not obtained at enrollment will be obtained daily for up to7 days. Length of 
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mechanical ventilator days and ICU length of stay will be calculated at discharge from the PICU. Research data (see list 
below) will be obtained daily for up to7 days. 
 
Existing data-  Cerner medication orders, demographic information (age, gender, weight) , length of mechanical 
ventilation days (VLOS), ICU length of stay 
Research data –  
Collected daily -WAT-1,  opioid taper rate (total MEK per day) 
Collected at time of study enrollment- calculation of PIM2, calculation of peak opioid (MEK) dose and opioid cumulative 
dose (MEK) plus duration (in days) of opioid exposure prior to initiation of opioid taper. 
 
 
 
D.  RECRUITMENT PLAN 
Describe in detail your plans for the recruitment of subjects including: (1) how potential subjects will be identified 
(e.g., school personnel, health care professionals, etc), (2) how you will get the names and contact information for 
potential subjects, and (3) who will make initial contact with these individuals (if relevant) and how that contact will 
be done.  If you plan to involve special cases of subjects, such as children, pregnant women, human fetuses, neonates, 
prisoners or others who are likely to be vulnerable, describe any special recruitment procedures for these populations. 
 
 
Participants will be recruited from a pediatric intensive care population within a 12 bed unit. Notification of ongoing study 
will be provided via laminated flier in each room. Potential participants will be identified by the student investigator 
through daily discussion with PICU health care professionals. The student investigator will make initial contact with the 
potential participants at the time of enrollment. At the time of initial contact, the student investigator will explain the study, 
answer questions and obtain permission from the parent or legal guardian. 
 
 
 
E.  POTENTIAL RISKS 
Describe potential risks whether physical, psychological, social, legal, or other and assess their likelihood and 
seriousness.  Where appropriate, describe alternative treatments and procedures that might be advantageous to the 
subjects. 
 
Since the study is observational, there will be no change in standard of care. Breach of confidentiality and invasion of 
privacy are potential risks. Likelihood of occurrence is minimal. 
 
 
 
F.  RISK REDUCTION 
Describe the procedures for protecting against or minimizing potential risk.  Where appropriate, discuss provisions 
for ensuring necessary medical or professional intervention in the event of adverse events to the subjects.  Also, where 
appropriate, describe the provisions for monitoring the data collected to ensure the safety of subjects. 
 
The bedside nurse will inform the student PI when routine care (assessments, vital signs) will be delivered, so that no 
additional participant stimulation will occur.  Parents or legal guardians of participants will be given a copy of the 
permission form. All forms and materials will be stored in a locked cabinet in a locked room. All forms will be coded with 
an assigned participant number. All data entered on computer will be linked to the participant number. Participant 
identifiers will be destroyed on entering data on computer. Data analysis will be reported in aggregate. 
 
 
G.  ADDITIONAL SAFEGUARDS IF ANY PARTICIPANTS WILL BE VULNERABLE  
Describe any additional safeguards to protect the rights and welfare of participants if you plan to involve special cases 
of subjects, such as children, pregnant women, human fetuses, neonates, prisoners or others who are likely to be 
vulnerable.  Safeguards to protect the rights and welfare of participants might relate to Inclusion/Exclusion Criteria: 
(“Adults with moderate to severe cognitive impairment will be excluded.”  “Children must have diabetes.  No normal 
controls who are children will be used.”)  Consent: (“Participants must have an adult care giver who agrees to the 
participant taking part in the research and will make sure the participant complies with research procedures.”  
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“Adults must be able to assent.  Any dissent by the participant will end the research procedures.”)  Benefit: 
(“Individuals who have not shown benefit to this type of drug in the past will be excluded.”).   
 
Legal guardians of participants must give permission for enrollment of participant in study. The student investigator has 
expertise in working with young infants and children. 
Exclusion criteria: 
No infants less than 2 weeks of age will be included; no children older than 21 years will be included. .Since one of the 
variables of the WAT-1 is restlessness, children with paralysis of one or more limbs or who are receiving neuroparalytics 
will be excluded.  
Since this is a descriptive study, no change in medical plan is anticipated.  
 
 
 
H.  CONFIDENTIALITY 
Describe how the confidentiality of data collected as part of this project will be protected including pre-screening data 
(e.g., physical controls on the data; access controls to the data; coding of data; legal controls, such as a Federal 
Certificate of Confidentiality; statistical methods; or reporting methods). 
 
Each participant will be assigned a number for this descriptive study. All data will be safeguarded by storage in a password 
protected electronic file. Only the student investigator will have access. Only the researchers listed on this research plan 
will be shown the data. Since the data obtained will be de-identified and the data will be reported in aggregate for the final 
report and publications, it will not be possible to identify any individual participant. 
 
 
 
I.  PRIVACY 
Describe how the privacy interests of subjects will be protected where privacy refers to persons and their interests in 
controlling access to themselves, and assess their likely effectiveness.  Identify what steps you will take for subjects to 
be comfortable: (1) in the research setting and (2) with the information being sought and the way it is sought. 
 
1. If the child is awake during data collection, the student PI will establish rapport with the participant. The student 
investigator has over twenty years experience as a pediatric nurse- including over 7 years experience as a PICU 
nurse.  
2. All efforts to remain unobtrusive will be attempted during data collection of asleep participants  
3. The student PI will collaborate with the bedside nurse on timing of data collection in order to respect the comfort 
and privacy of the participant. No personal data will be collected or recorded. All data collected will be stored in a 
password protected database. 
 
 
 
J.  RISK/BENEFIT 
Discuss why the risks to subjects are reasonable in relation to the anticipated benefits to subjects and in relation to the 
importance of the knowledge that may reasonably be expected to result.  If a test article (investigational new drug, 
device, or biologic) is involved, name the test article and supply the FDA approval letter. 
 
This is not a treatment study. There are no direct benefits from participation in the study. Since this is an observational 
study, no more than minimal risk is anticipated. Potential benefits of this study include addition of empirical evidence to 
the sparse fund of literature on the subject of opioid tapering in children. To the best of the investigator’s knowledge, this 
will be the first observational study measuring signs and symptoms and severity of opioid withdrawal in children using the 
recently validated opioid withdrawal instrument – WAT-1. Predicted long term benefit of the study data will be eventual 
translation of the knowledge into clinical decision-making that ensures optimal assessment based management of opioid 
withdrawal in children. 
 
 
 
K. COMPENSATION PLAN 
Compensation for subjects (if applicable) should be described, including possible total compensation, any proposed 
bonus, and any proposed reductions or penalties for not completing the project. 
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No compensation will be offered 
 
 
 
L.  CONSENT ISSUES 
 
1.  CONSENT PROCESS 
Indicate who will be asked to provide consent/assent, who will obtain consent/assent, what language (e.g., English, 
Spanish) will be used by those obtaining consent/assent, where and when will consent/assent be obtained, what steps 
will be taken to minimize the possibility of coercion or undue influence, and how much time will subjects be afforded 
to make a decision to participate. 
 
The parent/legal guardian will be asked to provide permission for those children <18 years of age. For those patients aged 
18 to 21 years, the Legal Authorized Representative (LAR) will be approached for consent. The student PI will obtain 
permission using the English language. The parent/ legal guardian will be approached for permission when the student PI 
has identified that the child will meet study inclusion criteria within 24 hours. The permission will be obtained at the 
bedside when possible. Explanation of the study will be provided in writing and verbally. The parent/legal guardian will be 
offered a hard copy of the permission to review overnight. 
Since the child will be receiving sedatives and analgesics, waiver of assent is requested.  
 
 
2.  SPECIAL CONSENT PROVISIONS 
If some or all subjects will be cognitively impaired, or have language/hearing difficulties, describe how capacity for 
consent will be determined. Please consider using the VCU Informed Consent Evaluation Instrument available at 
http://www.research.vcu.edu/irb/guidance.htm.  If you anticipate the need to obtain informed consent from legally 
authorized representatives (LARs), please describe how you will identify an appropriate representative and ensure 
that their consent is obtained.  Guidance on LAR is available at http://www.research.vcu.edu/irb/wpp/flash/XI-3.htm.  
 
NA 
 
 
3.  If request is being made to WAIVE SOME OR ALL ELEMENTS OF INFORMED CONSENT FROM SUBJECTS OR 
PERMISSION FROM PARENTS, explain why: (1) the research involves no more than minimal risk to the subjects, (2) the 
waiver or alteration will not adversely affect the rights and welfare of the subjects, (3) the research could not 
practicably be carried out without the waiver or alteration; AND (4) whether or not subjects will be debriefed after 
their participation.  Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/XI-1.htm..  NOTE: Waiver is 
not allowed for FDA-regulated research unless it meets FDA requirements for Waiver of Consent for Emergency 
Research (see below). 
 
NA 
 
 
4.  If request is being made to WAIVE DOCUMENTATION OF CONSENT, provide a justification for waiver based on one of 
the following two elements AND include a description of the information that will be provided to participants: (1) the 
only record linking the subject and the research would be the consent document and the principal risk would be 
potential harm resulting from a breach of confidentiality.  Subject will be asked whether they want documentation 
linking them with the research, and each subject’s wishes will govern; or (2) the research presents no more than 
minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of 
the research context.  Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/wpp_guide.htm#XI-2.htm 
 
NA 
 
 
5.  If applicable, explain the ASSENT PROCESS for children or decisionally impaired subjects.  Describe the 
procedures, if any, for re-consenting children upon attainment of adulthood. Describe procedures, if any, for 
consenting subjects who are no longer decisionally impaired.  Guidance is available at 
http://www.research.vcu.edu/irb/wpp/flash/XV-2.htm and http://www.research.vcu.edu/irb/wpp/flash/XVII-7.htm. 
 
NA 
 
 
6.  If request is being made to WAIVE THE REQUIREMENT TO OBTAIN ASSENT from children  age 7 or higher, or 
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decisionally impaired subjects, explain why: (1) why some or all of the individuals  age 7 or higher will not be capable 
of providing assent based on their developmental status or impact of illness; (2) the research holds out a prospect of 
direct benefit not available outside of the research; AND/OR (3) [a] the research involves no more than minimal risk to 
the subjects, [b] the waiver or alteration will not adversely affect the rights and welfare of the subjects, [c] the 
research could not practicably be carried out without the waiver or alteration; AND [d] whether or not subjects will be 
debriefed after their participation.  Guidance is available at http://www.research.vcu.edu/irb/wpp/flash/XV-2.htm   
 
1. All children participating in this study will be critically ill and on sedatives and opioids hence will not be capable to 
provide assent. 3. [a]The research is an observational study that will not impact daily care of the child. [b] this waiver will 
not adversely affect the rights and welfare of the child, [c] the research could not be practicably carried out without the 
waiver [d] should the child awaken enough to understand, the child will be debriefed after their participation. 
(1)The researcher anticipates that the children enrolled in this study will be sedated and possibly unconscious during the 
initial opioid tapering efforts, thus, it would be inappropriate to approach the patient for assent. (2) no direct benefit is 
anticipated for the patients during the study. (3) [a]the non-experimental descriptive and correlational research involves no 
more than minimal risk to the participants [b] the waiver will not adversely affect the rights and welfare of the participants 
[c] the research could not practicably be carried out without waiver [d] where applicable, subjects may be debriefed after 
participation at the time the legal guardian(s) are debriefed. 
 
 
 
7. If request is being made to waive consent for emergency research, see guidance at 
http://www.research.vcu.edu/irb/wpp/flash/XVII-16.htm. 
 
NA 
 
 
8.  If applicable, address the following issues related to GENETIC TESTING: 
 
a. FUTURE CONTACT CONCERNING FURTHER GENETIC TESTING RESEARCH 
Describe the circumstances under which the subject might be contacted in the future concerning further participation 
in this or related genetic testing research. 
 
NA 
 
 
b. FUTURE CONTACT CONCERNING GENETIC TESTING RESULTS 
If planned or possible future genetic testing results are unlikely to have clinical implications, then a statement that the 
results will not be made available to subjects may be appropriate. If results might be of clinical significance, then 
describe the circumstances and procedures by which subjects would receive results. Describe how subjects might 
access genetic counseling for assistance in understanding the implications of genetic testing results, and whether this 
might involve costs to subjects. Investigators should be aware that federal regulations, in general, require that testing 
results used in clinical management must have been obtained in a CLIA-certified laboratory. 
 
NA 
 
 
c. WITHDRAWAL OF GENETIC TESTING CONSENT 
Describe whether and how subjects might, in the future, request to have test results and/or samples withdrawn in 
order to prevent further analysis, reporting, and/or testing. 
 
NA 
 
 
d. GENETIC TESTING INVOLVING CHILDREN OR DECISIONALLY IMPAIRED SUBJECTS 
Describe procedures, if any, for consenting children upon the attainment of adulthood. Describe procedures, if any, 
for consenting subjects who are no longer decisionally impaired. 
 
NA 
 
 
e. CONFIDENTIALITY 
Describe the extent to which genetic testing results will remain confidential and special precautions, if any, to protect 
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confidentiality. 
 
NA 
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new pediatric nurses hired) 
 
Central Venous Catheters. Resident Noon Lecture series. October of 1999, 2000, 2001;July 
2002;July 14,2003; August 13, 2004 
 
Facilitator for Pediatric End of Life Resident Noon Lecture series. 2001, 2002, 2003,2004, 
2005,2006, 2007 
 
Bugs, Bugs, Everywhere. Survival Skills for School Nurses. Virginia Museum of Fine Arts- 
August  2002 
 
“Fever, Neutropenia & Sepsis”. Pediatric Oncology Core. –MCV-May 7, 2002 
 
Omas… and other Pediatric Cancers. Inservice radiology nurses September 11, 2003; Inservice 
pediatric nurses  2003, April 27, 2005; NUR 649 November 14, 2005. 
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“Pain Management for Children”.  Hematology Core Class for Parents. October 10, 2003 
 
“Anatomic and Physiologic Differences between Adults and Children”. Pediatric Clinical Byte. 
–VCUMC- October 23, 2003 
 
Infants. Pediatric Clinical Byte. –VCUMC-October 23, 2003 
 
End of Life Care for Children. Nursing 649 VCU School of Nursing. December 1, 2003; 
October 4, 2004; November 14, 2005 
 
Pediatric Pain Management. Nursing 649 VCU School of Nursing November 14, 2005. 
 
Boo boos, Ouchies and Other Owies. Pediatric Clinical Byte. September 22, 2005; pediatric 
resident noon conference; September 23, 2005 
 
Symptom Management. Pediatric Palliative Care. ELNEC conference for nurses.  March 17, 
2005(VCUMC/  Association of Pediatric Oncology Nurses); October 6, 2005(VCUMC); 
September 8,2006(VCUMC); September 17, 2007; October 10,2008 (VCUMC); October 
20,2010 (VCUMC) 
 
Pain Management.  Pediatric Palliative Care, ELNEC conference for nurses.  September 18, 
2007; October 9,2008 (VCUMC); October 9, 2009 (VCUMC);October 21, 2010(VCUMC) 
 
Research….  Pediatric Hematology Oncology Core #1.  VCUMC April 15,2005 
 
Pediatric Palliative Care. Bereavement Coordinators Meeting. VCUMC. March 7, 2006. 
 
Care of the Child at the Time of Death. Pediatric Resident Lecture. May 24, 2006 
 
Principles of Palliative Care. Perinatal/Neonatal Palliative Care Conference. October 2, 2006 
 
Achieving Quality Palliative Care- ELNEC Core conference for nurses. January 24, 2007; 
ELNEC Critical Care, November 2, 2007; ELNEC Critical Care, Richmond VA, December 4, 
2009. 
 
Introduction to Pediatric Palliative Care. Nursing Pediatric Palliative Care Core.  March 13, 
2007 
 
Ethics panel discussion: Futile treatment. Keynote Presentation.Trauma Nursing Symposium; 
The Trauma Nursing Spectrum: Beyond the Cutting Edge. Richmond Convention Center. April 
30, 2007 
 
Pediatric Pain Management.  Noon conference. August 30, 2007 
 
Case studies in Pediatric Palliative Care.  Pediatric Palliative Care Core #2.  October 9, 2007 
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Pain Management in the Pediatric Population. NRP Best Practices Seminar. January 15, 2008 
 
Pediatric Pain Case Studies. NRP Best Practices Seminar. March 10, 2008 
 
Pediatric Pain Case Studies- cognitive impairment. July 10, 2008 
 
 
VCU School of Nursing Guest Lectures 
Pediatric Lab Interpretation – Anemia. November 2001,2002; October 9, 2003. VCU SON 
NUR 511 
 
Pain Management in Children. Nursing 345. VCU School of Nursing. February 22, 2008.  
 
Pediatric Hematology. Nursing 345. VCU School of Nursing.  April 4, 2008. 
 
Pediatric Oncology. Nursing 345. VCU School of Nursing.  April 4, 2008. 
 
EOL care in children. Nursing 345. VCU School of Nursing.  April 11, 2008 
 
Omas… and other Pediatric Cancers. ; NUR 649 November 14, 2005 
 
Nursing Care of the Child and Family at the End of Life. Nursing 410 VCU School of Nursing. 
December 5, 2003 
 
MEMBERSHIP IN HONORARY AND PROFESSIONAL SOCIETIES 
 
National Association of Pediatric Nurse Associates & Practitioners 1997 - present 
National Association of Pediatric Nurse Associates & Practitioners – Virginia 
Chapter 
- Public Relations Chair 1999-2001 
- President 2001-2002 
Virginia Council of Nurse Practitioners 1996 - present 
Pediatric Oncology Group - contributing member 1997 – 2000 
Children’s Oncology Group – full member 2000- 2006 
Association of Pediatric Oncology Nurses 2000 – present 
Sigma Theta Tau – Omega Chapter 2003 – present 
 -    Vice President 2003 to 2005 
Noah’s Children – Pediatric Hospice Board member; Education subcommittee 2003 to present 
Children’s Hospice International 2005 to 2008 
Hospice and Palliative Care Nurses Association -2005 to present 
American Society for Pain Management Nursing- 2006 to present 
Southern Nursing Research Society – 2008 to present 
American Pain Society – 2011 to present 
 
Manuscript Reviewer for Journals or Textbooks 
Ad Hoc Reviewer. Heart and Lung. 2011 
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HONORS / AWARDS 
 
Barbara Farley Scholarship, awarded for leadership to graduate student, VCUHS Week of the 
Nurse 2010 
 
 HOSPITAL SERVICE 
    
o Nursing Services Professional Practice Council 2001-2003 
o Pediatric Professional Practice Council (nursing) – Chairman 2001 – 2003 
o Standards of Practice Council 2002- 2003 
o VCU Health Systems Pain Council 2001 - present 
o Pediatric Pain Council – Chair 2001- present 
o Medicine and Pediatrics Leadership Committee –2001-present 
o Children’s Oncology Group End of Life Education Task Force – 2000 to 2006 
o Pediatric Compassionate Care Committee – 2001 to 2004 
o Discharge Task Force 1997 to 1999 
o Children’s Professional Practice Council – 2001 to present 
o Pediatric Nursing Conference Planning Committee – conference October 2002 
o Oncology Nursing Leadership –2003 to 2005 
o Oncology Nursing Education Committee – 2003 to 2005 
o Pediatric Palliative Care Task Force- 2003 to 2005 
o Pediatric APN Council – co-chair 2005 to 2009 
o Advanced Practice Nursing steering committee- 2006 to 2007 
o Nursing Research Advisory Council – co-chair – 2008 to present 
o Council of Advanced Practice Nursing  
– CAPN Grand Rounds subcommittee- 2008 to 2009 
-  CAPN Executive Board - 2009 to present 
- Vice Chair August 2010 to December 2011 
- Chair 2012 to present 
  
 
 
 
 
